<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="36433"><DrugName>mocetinostat dihydrobromide</DrugName><DrugNamesKey><Name id="42908524">mocetinostat</Name><Name id="42896854">mocetinostat dihydrobromide</Name></DrugNamesKey><DrugSynonyms><Name><Value>MG-4230</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>MG-4915</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>MG-5026</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>MGCD-0103</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HDAC inhibitors (cancer), MethylGene</Value></Name><Name><Value>MGCD-0103 (oral), MethylGene/Taiho/Pharmion</Value></Name><Name><Value>histone deacetylase inhibitor (cancer), MethylGene/ Taiho/ Pharmion</Value></Name><Name><Value>MG-0103</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MGCD-3650</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>histone deacetylase inhibitor (cancer), MethylGene/Taiho/Celgene</Value></Name><Name><Value>MGCD-0103 (oral), MethylGene/Taiho/Celgene</Value></Name><Name><Value>mocetinostat dihydrobromide</Value><Types><Type>USAN</Type></Types></Name><Name><Value>mocetinostat</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>MGCD-103</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>501683-07-4</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>414872-01-8</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>362670-00-6</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>726169-73-9</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>944537-89-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23090">MethylGene Inc</CompanyOriginator><CompaniesPrimary><Company id="1085701">Mirati Therapeutics Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="15331">Celgene Corp</Company><Company id="18720">Taiho Pharmaceutical Co Ltd</Company><Company id="23090">MethylGene Inc</Company><Company id="29253">Pharmion Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="36433" type="Drug"><TargetEntity id="342540" type="siDrug">Mocetinostat dihydrobromide</TargetEntity></SourceEntity><SourceEntity id="1085701" type="Company"><TargetEntity id="5039800567" type="organizationId">Mirati Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="15331" type="Company"><TargetEntity id="4295905897" type="organizationId">Celgene Corp</TargetEntity></SourceEntity><SourceEntity id="18720" type="Company"><TargetEntity id="5000071049" type="organizationId">Taiho Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="23090" type="Company"><TargetEntity id="4295863174" type="organizationId">MethylGene Inc</TargetEntity></SourceEntity><SourceEntity id="29253" type="Company"><TargetEntity id="4295899308" type="organizationId">Pharmion Corp</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"></TargetEntity><TargetEntity id="10028533" type="MEDDRA"></TargetEntity><TargetEntity id="D011289" type="MeSH"></TargetEntity><TargetEntity id="-376765165" type="omicsDisease"></TargetEntity><TargetEntity id="711" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="161" type="ciIndication"><TargetEntity id="C81" type="ICD10"></TargetEntity><TargetEntity id="201" type="ICD9"></TargetEntity><TargetEntity id="10020206" type="MEDDRA"></TargetEntity><TargetEntity id="D006689" type="MeSH"></TargetEntity><TargetEntity id="98293" type="ORPHANET"></TargetEntity><TargetEntity id="-1008729809" type="omicsDisease"></TargetEntity><TargetEntity id="701" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"></TargetEntity><TargetEntity id="519" type="ORPHANET"></TargetEntity><TargetEntity id="-1550871001" type="omicsDisease"></TargetEntity><TargetEntity id="686" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"></TargetEntity><TargetEntity id="690" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1771" type="ciIndication"><TargetEntity id="10044412" type="MEDDRA"></TargetEntity><TargetEntity id="D002295" type="MeSH"></TargetEntity><TargetEntity id="-807613677" type="omicsDisease"></TargetEntity><TargetEntity id="677" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="199" type="ciIndication"><TargetEntity id="10024288" type="MEDDRA"></TargetEntity><TargetEntity id="D007938" type="MeSH"></TargetEntity><TargetEntity id="-609576380" type="omicsDisease"></TargetEntity><TargetEntity id="683" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2380" type="ciIndication"><TargetEntity id="C67" type="ICD10"></TargetEntity><TargetEntity id="188.9" type="ICD9"></TargetEntity><TargetEntity id="10005003" type="MEDDRA"></TargetEntity><TargetEntity id="-2101107804" type="omicsDisease"></TargetEntity><TargetEntity id="578" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="316" type="ciIndication"><TargetEntity id="10003899" type="MEDDRA"></TargetEntity><TargetEntity id="-1829786210" type="omicsDisease"></TargetEntity><TargetEntity id="699" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"></TargetEntity><TargetEntity id="D008228" type="MeSH"></TargetEntity><TargetEntity id="547" type="ORPHANET"></TargetEntity><TargetEntity id="-1008757452" type="omicsDisease"></TargetEntity><TargetEntity id="703" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"></TargetEntity><TargetEntity id="613" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="7315" type="Action"><TargetEntity id="5443" type="Mechanism">Caspase 7 Activators</TargetEntity><TargetEntity id="5282" type="Mechanism">Procaspase 7 Activators</TargetEntity></SourceEntity><SourceEntity id="7844" type="Action"><TargetEntity id="1915" type="Mechanism">Histone Deacetylase 2 (HDAC2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="7850" type="Action"><TargetEntity id="2408" type="Mechanism">Histone Deacetylase 4 (HDAC4) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7841" type="Action"><TargetEntity id="1749" type="Mechanism">Histone Deacetylase 1 (HDAC1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7847" type="Action"><TargetEntity id="3062" type="Mechanism">Histone Deacetylase 3 (HDAC3) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="7303" type="Action"><TargetEntity id="3033" type="Mechanism">Procaspase 3 Activators</TargetEntity><TargetEntity id="1773" type="Mechanism">Caspase 3 Activators</TargetEntity></SourceEntity><SourceEntity id="7871" type="Action"><TargetEntity id="4010" type="Mechanism">Histone Deacetylase 11 (HDAC11) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00326" type="ciTarget"><TargetEntity id="16512970868363" type="siTarget">Caspase-3</TargetEntity><TargetEntity id="912" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00330" type="ciTarget"><TargetEntity id="2251946858403" type="siTarget">Caspase-7</TargetEntity><TargetEntity id="913" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00923" type="ciTarget"><TargetEntity id="205759791330653" type="siTarget">Histone deacetylase 1</TargetEntity><TargetEntity id="-1584981221" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00924" type="ciTarget"><TargetEntity id="7769724330663" type="siTarget">Histone deacetylase 2</TargetEntity><TargetEntity id="-1539608840" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00925" type="ciTarget"><TargetEntity id="198643746488413" type="siTarget">Histone deacetylase 3</TargetEntity><TargetEntity id="2539" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00926" type="ciTarget"><TargetEntity id="67462328697593" type="siTarget">Histone deacetylase 4</TargetEntity><TargetEntity id="-1140757519" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00933" type="ciTarget"><TargetEntity id="1003550798853" type="siTarget">Histone deacetylase 11</TargetEntity><TargetEntity id="2536" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3713">Advanced solid tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="161">Hodgkins disease</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1771">Transitional cell carcinoma</Indication><Indication id="199">Leukemia</Indication><Indication id="2380">Bladder cancer</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="316">B-cell lymphoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="7847">Histone deacetylase-3 inhibitor</Action><Action id="7871">Histone deacetylase-11 inhibitor</Action><Action id="7315">Caspase-7 stimulator</Action><Action id="7303">Caspase-3 stimulator</Action><Action id="7850">Histone deacetylase-4 inhibitor</Action><Action id="7844">Histone deacetylase-2 inhibitor</Action><Action id="7841">Histone deacetylase-1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1589">Apoptosis stimulator</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-04-16T07:21:40.000Z</LastModificationDate><ChangeDateLast>2019-04-12T00:00:00.000Z</ChangeDateLast><AddedDate>2001-10-17T16:17:02.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1085701" linkType="Company"&gt;Mirati Therapeutics&lt;/ulink&gt;, following the transfer of &lt;ulink linkID="23090" linkType="Company"&gt;MethylGene&lt;/ulink&gt;'s assets to the US,  is developing  the oral isoform-selective  histone deacetylase (HDAC)-1, -2, -3, -11 and  -4 inhibitor, mocetinostat dihydrobromide (MGCD-0103, MG-0103, MGCD-103), for the potential treatment of advanced solid tumors, primarily in non-small cell lung cancer (NSCLC) in combination with &lt;ulink linkID="81193" linkType="Drug"&gt;durvalumab&lt;/ulink&gt; [&lt;ulink linkID="1908755" linkType="Reference"&gt;1908755&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2015, Mirati  agreed to conduct a phase I/II trial of  mocetinostat plus &lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt;'s &lt;ulink linkID="81193" linkType="Drug"&gt;durvalumab&lt;/ulink&gt; for NSCLC [&lt;ulink linkID="1683695" linkType="Reference"&gt;1683695&lt;/ulink&gt;]; in May 2016,  the phase I/II study began  in the US in   patients  with advanced or metastatic solid tumors and NSCLC [&lt;ulink linkID="1776217" linkType="Reference"&gt;1776217&lt;/ulink&gt;]; in March 2017, Mirati was planning to provide an update  in mid 2017 and recruitment of the phase Ib/II trial was  ongoing [&lt;ulink linkID="1907374" linkType="Reference"&gt;1907374&lt;/ulink&gt;],  [&lt;ulink linkID="1908755" linkType="Reference"&gt;1908755&lt;/ulink&gt;]; In April 2018, phase II data from NSCLC patients were reported [&lt;ulink linkID="2027242" linkType="Reference"&gt;2027242&lt;/ulink&gt;]. In November 2016, a phase II study was initiated in US to asses the safety and efficacy of &lt;ulink linkID="53225" linkType="Drug"&gt;glesatinib&lt;/ulink&gt;, &lt;ulink linkID="63193" linkType="Drug"&gt;sitravatinib&lt;/ulink&gt; or mocetinostat in combination with &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; in patients with advanced or metastatic NSCLC; in May 2018, the study was ongoing [&lt;ulink linkID="1873735" linkType="Reference"&gt;1873735&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="18720" linkType="Company"&gt;Taiho Pharmaceutical&lt;/ulink&gt;   had acquired rights to develop the drug in Southeast Asia  in October 2003   [&lt;ulink linkID="509670" linkType="Reference"&gt;509670&lt;/ulink&gt;]; however, no further development has since been reported.&lt;/para&gt;&lt;para&gt;The drug was previously being developed for other cancer settings. In August 2006, a phase II study for refractory or relapsed Hodgkins lymphoma began [&lt;ulink linkID="685653" linkType="Reference"&gt;685653&lt;/ulink&gt;], [&lt;ulink linkID="783173" linkType="Reference"&gt;783173&lt;/ulink&gt;]; in February 2009, the trial was terminated [&lt;ulink linkID="783173" linkType="Reference"&gt;783173&lt;/ulink&gt;]. In October 2006, a phase I/II trial of mocetinostat in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; (Gemzar) for solid tumors, including pancreatic cancer, began [&lt;ulink linkID="783168" linkType="Reference"&gt;783168&lt;/ulink&gt;], [&lt;ulink linkID="734584" linkType="Reference"&gt;734584&lt;/ulink&gt;]; in October 2007, interim data were presented [&lt;ulink linkID="844673" linkType="Reference"&gt;844673&lt;/ulink&gt;]; in December 2008, the trial was completed [&lt;ulink linkID="783168" linkType="Reference"&gt;783168&lt;/ulink&gt;]. In February 2007, a phase II trial for CLL commenced [&lt;ulink linkID="783176" linkType="Reference"&gt;783176&lt;/ulink&gt;]; in December 2008, the trial was completed [&lt;ulink linkID="783176" linkType="Reference"&gt;783176&lt;/ulink&gt;]. By June 2008, phase II BCL development was ongoing [&lt;ulink linkID="910834" linkType="Reference"&gt;910834&lt;/ulink&gt;].  In June 2008, a phase II trial began to assess mocetinostat dihydrobromide as a single agent or as a combination with &lt;ulink linkID="37370" linkType="Drug"&gt;azacitidine&lt;/ulink&gt; (Vidaza) in geriatric patients with newly diagnosed AML or high-risk MDS  [&lt;ulink linkID="920191" linkType="Reference"&gt;920191&lt;/ulink&gt;], [&lt;ulink linkID="920137" linkType="Reference"&gt;920137&lt;/ulink&gt;]; in December 2008, the trial was terminated due to the re-acquisition of rights from &lt;ulink linkID="15331" linkType="Company"&gt;Celgene&lt;/ulink&gt; [&lt;ulink linkID="920191" linkType="Reference"&gt;920191&lt;/ulink&gt;]. In October 2006, a phase I/II combination trial  for solid tumors was initiated [&lt;ulink linkID="734584" linkType="Reference"&gt;734584&lt;/ulink&gt;]; in December 2008, the trial was completed [&lt;ulink linkID="783168" linkType="Reference"&gt;783168&lt;/ulink&gt;]. In October 2014, a phase II study  was initiated in the US in patients with advanced urothelial carcinoma [&lt;ulink linkID="1605498" linkType="Reference"&gt;1605498&lt;/ulink&gt;]. By September 2006, phase II trials for non-Hodgkin's lymphoma (NHL) had commenced  [&lt;ulink linkID="690628" linkType="Reference"&gt;690628&lt;/ulink&gt;]; in February 2012, the trial was completed [&lt;ulink linkID="783174" linkType="Reference"&gt;783174&lt;/ulink&gt;]. In December 2006, phase II trials for myelodysplastic syndrome (MDS) and AML began [&lt;ulink linkID="749530" linkType="Reference"&gt;749530&lt;/ulink&gt;]; in December 2008, the trial was terminated [&lt;ulink linkID="783171" linkType="Reference"&gt;783171&lt;/ulink&gt;]. By March 2014, the company initiated a dose confirmation study for MDS [&lt;ulink linkID="1535623" linkType="Reference"&gt;1535623&lt;/ulink&gt;]; however, no development has been reported. In July 2014, the drug was listed as being under phase II development for bladder cancer, diffuse large B-cell lymphoma (DLBCL) and MDS [&lt;ulink linkID="1574636" linkType="Reference"&gt;1574636&lt;/ulink&gt;]; however, in March 2017, Mirati stated that a level of activity or response to single agent mocetinostat justifying the continuation of  development in bladder cancer, NHL or MDS  settings was not seen, and those indications were discontinued [&lt;ulink linkID="1908755" linkType="Reference"&gt;1908755&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In April 2003, MethylGene was assigned &lt;ulink linkID="PA3088464" linkType="Patent"&gt;US-06541661&lt;/ulink&gt;, covering compounds and methods for inhibiting HDAC enzymatic activity as well as the compositions and methods for treating cell proliferative diseases and conditions. In March 2017, Mirati noted that two US patents covering mocetinostat generically and specifically containing both composition of matter and method of use claims had been granted; mocetinostat's exclusivity  extends to 2022 prior to legal or regulatory extensions, including any patent term extension that may be available under the Hatch Waxman Act [&lt;ulink linkID="1908755" linkType="Reference"&gt;1908755&lt;/ulink&gt;]. In March 2018, Mirati stated that it owned 17 granted patents covering mocetinostat and other HDAC inhibitors that expire between 2022 and 2035 [&lt;ulink linkID="2014215" linkType="Reference"&gt;2014215&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2007, the drug received US Orphan status for Hodgkin's lymphoma [&lt;ulink linkID="824047" linkType="Reference"&gt;824047&lt;/ulink&gt;], [&lt;ulink linkID="824008" linkType="Reference"&gt;824008&lt;/ulink&gt;]. In February 2008, the drug received US Orphan status for AML [&lt;ulink linkID="876738" linkType="Reference"&gt;876738&lt;/ulink&gt;], [&lt;ulink linkID="877220" linkType="Reference"&gt;877220&lt;/ulink&gt;]. In June 2014, mocetinostat received Orphan status for MDS [&lt;ulink linkID="1570068" linkType="Reference"&gt;1570068&lt;/ulink&gt;]. In August 2014, orphan applications for bladder cancer and DLBCL had been submitted [&lt;ulink linkID="1584145" linkType="Reference"&gt;1584145&lt;/ulink&gt;]. Later the month, the US FDA granted Orphan Drug designation to the drug for DLBCL [&lt;ulink linkID="1584498" linkType="Reference"&gt;1584498&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2007, the  EMEA granted the drug Orphan status   for Hodgkin's lymphoma [&lt;ulink linkID="832836" linkType="Reference"&gt;832836&lt;/ulink&gt;], [&lt;ulink linkID="832742" linkType="Reference"&gt;832742&lt;/ulink&gt;]. In February 2008, the EMEA  granted the drug Orphan status for AML [&lt;ulink linkID="875497" linkType="Reference"&gt;875497&lt;/ulink&gt;], [&lt;ulink linkID="875488" linkType="Reference"&gt;875488&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In July 2008, MethylGene and Celgene suspended enrollment in all clinical trials, following a recommendation by a standing internal safety committee which noted 19 instances of pericarditis. The 400 patients currently enrolled in the studies, who had no pericarditis symptoms, would continue treatment as normal as the events tended to occur during the first cycle of treatment. The trial's investigators believed that half of the cases were not drug-related [&lt;ulink linkID="927187" linkType="Reference"&gt;927187&lt;/ulink&gt;]. In August 2008, the FDA placed a partial clinical hold on new patient enrollment until the companies submitted  data and an action plan to reduce the risk of pericarditis for patients. Currently enrolled patients who had no signs or symptoms of pericarditis or pericardial effusion  would  continue in their respective studies. At that time, the companies were working with the agency to complete a package  to  recommence enrollment as soon as possible  [&lt;ulink linkID="935821" linkType="Reference"&gt;935821&lt;/ulink&gt;]. In September 2009, the FDA lifted the partial clinical hold and patient enrollment was allowed to resume, after no link between the drug and pericarditis or pericardial effusion was observed. Patients with cardiac abnormalities would be excluded from enrollment  and all patients would undergo electrocardiogram and echocardiography monitoring throughout the study [&lt;ulink linkID="1043971" linkType="Reference"&gt;1043971&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2016, an interventional, non-randomized, parallel-group, open-label phase II study (&lt;ulink linkID="278331" linkType="Protocol"&gt;NCT02954991&lt;/ulink&gt;: MRTX-500) was initiated in US to asses the safety and efficacy of &lt;ulink linkID="53225" linkType="Drug"&gt;glesatinib&lt;/ulink&gt;, &lt;ulink linkID="63193" linkType="Drug"&gt;sitravatinib&lt;/ulink&gt; or mocetinostat in combination with &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; in patients (expected n = 209) with advanced or metastatic NSCLC. At that time, the study was expected to complete in April 2019; in May 2018, the study was ongoing  [&lt;ulink linkID="1873735" linkType="Reference"&gt;1873735&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In August 2017, a single-arm, open-label, interventional phase I/Ib trial (&lt;ulink linkID="305528" linkType="Protocol"&gt;NCT03220477&lt;/ulink&gt;; 17-241) was initiated in the US in patients (expected n = 57) with advanced NSCLC to test the safety of a combination of three drugs, &lt;ulink linkID="70667" linkType="Drug"&gt;pembrolizumab&lt;/ulink&gt;, &lt;ulink linkID="58489" linkType="Drug"&gt;guadecitabine&lt;/ulink&gt; and mocetinostat. The primary outcome measure was number of patients with adverse events [&lt;ulink linkID="1964133" linkType="Reference"&gt;1964133&lt;/ulink&gt;]. In November 2017, recruitment was ongoing;   at that time, the trial was expected to complete in  July 2020   [&lt;ulink linkID="1964133" linkType="Reference"&gt;1964133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bladder cancer&lt;/subtitle&gt;In November 2014, a registration-enabling study was initiated in patients with bladder cancer who had mutations of CREBBP or EP300 genes. At that time, initial proof of concept data were expected in early 2015 [&lt;ulink linkID="1610402" linkType="Reference"&gt;1610402&lt;/ulink&gt;],  [&lt;ulink linkID="1584145" linkType="Reference"&gt;1584145&lt;/ulink&gt;]. In March 2015, initial proof of concept data were expected in mid-2015 [&lt;ulink linkID="1640488" linkType="Reference"&gt;1640488&lt;/ulink&gt;]. In August 2015, initial data were expected later in 2015 [&lt;ulink linkID="1684400" linkType="Reference"&gt;1684400&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Urothelial carcinoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2014, an open-label, single-arm, phase II study (&lt;ulink linkID="210119" linkType="Protocol"&gt;NCT02236195&lt;/ulink&gt;; 0103-018) was initiated in the US in patients (n = 15) with advanced urothelial carcinoma. The trial was expected to complete in December 2017 [&lt;ulink linkID="1605498" linkType="Reference"&gt;1605498&lt;/ulink&gt;].		By May 2015, 10 patients had been treated [&lt;ulink linkID="1666264" linkType="Reference"&gt;1666264&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;B cell lymphoma&lt;/subtitle&gt;In June 2008, data from an ongoing phase II trial were presented at the 44th annual ASCO meeting in Chicago, IL. Patients were enrolled at 85 or 110 mg; the 85 mg cohort was better tolerated [&lt;ulink linkID="910834" linkType="Reference"&gt;910834&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Chronic lymphocytic leukemia&lt;/subtitle&gt;In January 2007, a non-randomized, open-label phase II single-agent study (&lt;ulink linkID="41257" linkType="Protocol"&gt;NCT00431873&lt;/ulink&gt;, Trial 009) was initiated in the US and Canada in patients with CLL. The primary endpoint was overall response rate [&lt;ulink linkID="772361" linkType="Reference"&gt;772361&lt;/ulink&gt;], [&lt;ulink linkID="783176" linkType="Reference"&gt;783176&lt;/ulink&gt;]. In July 2007, the 40-patient,  2-year trial was to assess mocetinostat dihydrobromide dosed three times weekly [&lt;ulink linkID="812654" linkType="Reference"&gt;812654&lt;/ulink&gt;]. In October 2007, enrollment for this trial was ongoing [&lt;ulink linkID="835572" linkType="Reference"&gt;835572&lt;/ulink&gt;]; in December 2008, the trial was completed [&lt;ulink linkID="783176" linkType="Reference"&gt;783176&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Myelodysplastic syndrome and acute myelogenous leukemia&lt;/subtitle&gt;In March 2014, a potential registration trial in patients with MDS was planned in 2014 [&lt;ulink linkID="1535623" linkType="Reference"&gt;1535623&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2014, the company initiated a dose confirmation study for MDS [&lt;ulink linkID="1535623" linkType="Reference"&gt;1535623&lt;/ulink&gt;]; In May 2014, the company planned to report the data from the phase II trial by the end of 2014 [&lt;ulink linkID="1557480" linkType="Reference"&gt;1557480&lt;/ulink&gt;]; in June 2014, enrolment of patients with intermediate and high-risk MDS was ongoing for the trial to evaluate mocetinostat in combination with &lt;ulink linkID="37370" linkType="Drug"&gt;Vidaza&lt;/ulink&gt; [&lt;ulink linkID="1570068" linkType="Reference"&gt;1570068&lt;/ulink&gt;]. In August 2014, initial proof-of-concept data were expected by the end of 2014  [&lt;ulink linkID="1584145" linkType="Reference"&gt;1584145&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, the companies planned a three-arm, randomized phase II trial (Trial 013) for AML. The trial was to compare mocetinostat dihydrobromide as a single agent or as a combination with &lt;ulink linkID="37370" linkType="Drug"&gt;azacitidine&lt;/ulink&gt; (Vidaza). At that time, the company planned to begin the trial in the first quarter of 2008 [&lt;ulink linkID="835572" linkType="Reference"&gt;835572&lt;/ulink&gt;]. In June 2008, the phase II trial (&lt;ulink linkID="28602" linkType="Protocol"&gt;NCT00666497&lt;/ulink&gt;; 103 PH GL 2007 CL003) began. In the North American, European, randomized, open label study, 180 geriatric patients with newly diagnosed AML or high-risk MDS received 75 mg/m2/day of azacitidine for 5 days, 90 mg of mocetinostat dihydrobromide three times per week, or the combination of both   in 28-day cycles. The primary endpoint was overall response rate according to IWG. Secondary endpoints included duration of response, time to progression, progression-free survival, red blood cell transfusion independence, hematologic improvement, quality of life, safety and pharmacokinetics. At that time, the trial was expected to be completed by August 2010, with final data collection date for primary outcome measure set for June 2010 [&lt;ulink linkID="920191" linkType="Reference"&gt;920191&lt;/ulink&gt;], [&lt;ulink linkID="920137" linkType="Reference"&gt;920137&lt;/ulink&gt;]; in December 2008, the trial was terminated due to the re-acquisition of rights from Celgene [&lt;ulink linkID="920191" linkType="Reference"&gt;920191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, the company started an open-label phase II trial (&lt;ulink linkID="27296" linkType="Protocol"&gt;NCT00374296&lt;/ulink&gt;, Trial 007) in Canada and the US in 82 patients with MDS or AML who would receive 110 mg of mocetinostat dihydrobromide orally, three times a week for 4 weeks. The primary objective would be to determine efficacy. The trial would also assess safety, biomarkers and other predictive markers for mocetinostat dihydrobromide3 [&lt;ulink linkID="749530" linkType="Reference"&gt;749530&lt;/ulink&gt;], [&lt;ulink linkID="783171" linkType="Reference"&gt;783171&lt;/ulink&gt;]. In October 2007, the trial was amended to focus on enrolling elderly , untreated AML patients for whom an oral therapy was desired  [&lt;ulink linkID="835572" linkType="Reference"&gt;835572&lt;/ulink&gt;]; in December 2008, the trial was terminated [&lt;ulink linkID="783171" linkType="Reference"&gt;783171&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, MethylGene began a phase I/II trial (&lt;ulink linkID="27762" linkType="Protocol"&gt;NCT00324220&lt;/ulink&gt;, Trial 005) of mocetinostat dihydrobromide in combination with Vidaza for advanced MDS and AML. The phase I part of the 50-patient, multicenter study would assess the compatibility, safety and maximum tolerated does of oral mocetinostat dihydrobromide (35, 60, 90, 110, or 135 mg; n = 3, 3, 8, 6 and 3, respectively; first dose on day 5 of the first cycle) thrice-weekly with standard azacitidine therapy (75 mg/m2  qd for the first 7 days of each 28 day treatment cycle). Efficacy, pharmacodynamics and pharmacokinetics would also be assessed. The phase II portion would determine overall response rate [&lt;ulink linkID="634592" linkType="Reference"&gt;634592&lt;/ulink&gt;], [&lt;ulink linkID="783165" linkType="Reference"&gt;783165&lt;/ulink&gt;]. In December 2006, at the 48th ASH meeting in Orlando, FL, data from 23 patients given the 110 mg dose achieved a response rate of 30% [&lt;ulink linkID="749890" linkType="Reference"&gt;749890&lt;/ulink&gt;], [&lt;ulink linkID="749999" linkType="Reference"&gt;749999&lt;/ulink&gt;], [&lt;ulink linkID="748898" linkType="Reference"&gt;748898&lt;/ulink&gt;]. In June 2007, similar data were presented at the 43rd ASCO meeting in Chicago, IL, and it was reported that recruitment was to continue at the 90 mg dose [&lt;ulink linkID="801165" linkType="Reference"&gt;801165&lt;/ulink&gt;], [&lt;ulink linkID="796338" linkType="Reference"&gt;796338&lt;/ulink&gt;]. In October 2007, enrollment  in high-risk MDS and AML patients had been completed; at that time, the trial had been amended to focus and enroll additional patients with low-risk MDS [&lt;ulink linkID="835572" linkType="Reference"&gt;835572&lt;/ulink&gt;]. In December 2007, at the 49th ASH meeting in Atlanta, GA, it was disclosed that 37 evaluable patients had been registered. Complete responses were seen in nine patients and two experienced a partial response; six of these subjects were continuing with the treatment. Five discontinued treatment with the majority due to SAEs; the DLTs included nausea, vomiting, anorexia, diarrhea and dehydration. The MTD was decreased to 90 mg. No interaction was observed between 5-azacitidine and mocetinostat dihydrobromide  and, at that time, a randomized study of 5-azacitidine with or without mocetinostat dihydrobromide  in AML and MDS was planned [&lt;ulink linkID="859957" linkType="Reference"&gt;859957&lt;/ulink&gt;]. In April 2008, it was reported that the overall response rate for mocetinostat dihydrobromide was 36%, with a response rate of 43% in the 90 mg dose group [&lt;ulink linkID="893467" linkType="Reference"&gt;893467&lt;/ulink&gt;]. In June 2013,  further data from 66 patients were presented at the 49th ASCO meeting in Chicago, IL.   In the MDS and AML patients, the respective objective response rates after mocetinostat treatment were 61 and 32% and the respective disease control rates were 93 and 84%.  The median duration for overall survival was 12.9 months in the MDS cohort and 5.1 months in the AML cohort [&lt;ulink linkID="1427571" linkType="Reference"&gt;1427571&lt;/ulink&gt;]. In December 2013,  retrospective and subset analysis results were presented from the open-label study at the 55th ASH Meeting in New Orleans, LA. Among patients with percentage bone marrow blast at screening with 5 to 20%, 5 to 9%, 10 to 20%, no prior cancer therapy and prior cancer therapy, 13, 4, 9, 8 and 5 patients, respectively, had complete response(CR)/CR with incomplete blood count recovery (CRi) + partial response (PR); 2, 1, 1, 1 and 1 patient(s), respectively, had CR; 9, 3, 6, 6 and 3 patients, respectively, had Cri; 2, 0, 2, 1 and 1 patient(s), respectively, had PR; 7, 2, 5,4 and 3 patients, respectively, had stable disease [&lt;ulink linkID="1503078" linkType="Reference"&gt;1503078&lt;/ulink&gt;], [&lt;ulink linkID="1507348" linkType="Reference"&gt;1507348&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-Hodgkin's lymphoma&lt;/subtitle&gt;In May 2014, the company planned to initate a phase II trial in DLBCL patients in mid-2014. At that time, data were expected to be reported by the end of 2014 [&lt;ulink linkID="1557480" linkType="Reference"&gt;1557480&lt;/ulink&gt;]. In August 2014, initial proof-of-concept data were expected by the end of 2014  [&lt;ulink linkID="1584145" linkType="Reference"&gt;1584145&lt;/ulink&gt;]. In November 2014, a phase II trial was initiated  in patients with relapsed/refractory DLBCL with tumors harbor CREBBP or EP300 gene mutations and at that time initial proof of concept data were anticipated in early 2015 [&lt;ulink linkID="1610402" linkType="Reference"&gt;1610402&lt;/ulink&gt;]. In January 2015, the first patient was dosed in the open-label, single group assignment, safety/efficacy, investigator-sponsored trial (&lt;ulink linkID="214969" linkType="Protocol"&gt;NCT02282358&lt;/ulink&gt;; 14-106), in the US in patients (expected n = 54) with DLBCL (expected n = 27) and follicular lymphoma (expected n = 27). At that time, the study was expected to be completed in October 2016 [&lt;ulink linkID="1624527" linkType="Reference"&gt;1624527&lt;/ulink&gt;], [&lt;ulink linkID="1624317" linkType="Reference"&gt;1624317&lt;/ulink&gt;].   In March 2015, initial proof of concept data were expected in mid-2015 [&lt;ulink linkID="1640488" linkType="Reference"&gt;1640488&lt;/ulink&gt;]. In August 2015, initial data were expected later in 2015 [&lt;ulink linkID="1684400" linkType="Reference"&gt;1684400&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2007, an open-label, North American phase II trial (&lt;ulink linkID="40874" linkType="Protocol"&gt;NCT00543582&lt;/ulink&gt;, CL002, also presumed to be Trial 012) of mocetinostat dihydrobromide in combination with Vidaza (azacitidine) in relapsed or refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma was initiated. A total of 75 patients would be treated with 75 mg/m2 of Vidaza intravenously or subcutaneously plus an oral dose of mocetinostat dihydrobromide in 28 day cycles. Endpoints would include overall response rate, progression-free survival and duration of response. A pharmacokinetic equivalency study would also be conducted. In December 2007,  the trial was expected to complete in August 2008 [&lt;ulink linkID="866530" linkType="Reference"&gt;866530&lt;/ulink&gt;], [&lt;ulink linkID="866278" linkType="Reference"&gt;866278&lt;/ulink&gt;], [&lt;ulink linkID="866200" linkType="Reference"&gt;866200&lt;/ulink&gt;]; in December 2008, the trial was terminated due to the re-acquisition of rights from Celgene [&lt;ulink linkID="866530" linkType="Reference"&gt;866530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, a phase II trial (&lt;ulink linkID="28703" linkType="Protocol"&gt;NCT00359086&lt;/ulink&gt;, Trial 008) in patients with relapsed or refractory NHL began in the US and Canada. The open-label, single-agent trial would enroll up to 82 patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma. Subjects would receive an oral 110 mg dose of mocetinostat dihydrobromide, three times weekly for up to 2 years. The primary endpoint would be efficacy. Secondary endpoints would assess safety and biomarkers and predictive markers for the drug [&lt;ulink linkID="690628" linkType="Reference"&gt;690628&lt;/ulink&gt;], [&lt;ulink linkID="690867" linkType="Reference"&gt;690867&lt;/ulink&gt;], [&lt;ulink linkID="734568" linkType="Reference"&gt;734568&lt;/ulink&gt;], [&lt;ulink linkID="783174" linkType="Reference"&gt;783174&lt;/ulink&gt;]. In October 2007, enrollment was ongoing and was expected to be completed by the end of 2007; the company also planned to enroll 40 patients with follicular lymphoma for this trial  and predicted this part of the enrollment would continue into 2008  [&lt;ulink linkID="835572" linkType="Reference"&gt;835572&lt;/ulink&gt;]. In December 2007, clinical data were presented at the 49th ASH meeting in Atlanta, GA. mocetinostat dihydrobromide was initially dosed at 110 mg thrice-weekly in 4 week cycles, escalation to 135 mg or reductions to 85 and 60 mg were permitted based on patient tolerance. Patients enrolled later in the trial had starting doses of 85 mg, with escalation to 110 mg and reductions to 60 and 40 mg also permitted. By December 2007, 52 patients had been enrolled and 50 patients had been treated. Of 34 patients who had their tumors reassessed after initiation of treatment, 53% exhibited some level of tumor reduction and 35% exhibited 30% or greater reduction and 24% showed 40% or more reduction. A total of five responders had progression-free survival lasting 168 days or longer. Out of 50 safety-evaluable patients the most common drug-related toxicities at grade 3 or above were fatigue, neutropenia, thrombocytopenia and anemia. Mocetinostat dihydrobromide was found to be rapidly absorbed, disappeared biphasically and was still quantifiable 24 h post dose. The plasma half life was approximately 8 h. Cmax and AUC values were only slightly higher at treatment with 110 mg than 85 mg which suggested a trend towards saturable absorption. Significant inhibition of HDAC activity in PBMCs was observed in the majority of patients evaluated [&lt;ulink linkID="859829" linkType="Reference"&gt;859829&lt;/ulink&gt;]. In September 2009, following the lift of the partial clinical hold on patient enrollment by the FDA, patient recruitment was expected to resume [&lt;ulink linkID="1043971" linkType="Reference"&gt;1043971&lt;/ulink&gt;]; in February 2012, the trial was completed [&lt;ulink linkID="783174" linkType="Reference"&gt;783174&lt;/ulink&gt;]. In June 2013,  further data from  72 patients were presented at the 49th ASCO meeting in Chicago, IL. In the DLBCL and FL cohorts, the respective objective response rates were 17 and 10% and the respective disease control rates were 49 and 61% . the estimated median duration for overall survival was 8.3 months in the DLBCL cohort. The estimated median progression-free survival duration was 2.7 and 4 months in the DLBCL and FL cohorts, respectively. The tumor reduction was observed in 77% of patients in the DLBCL cohort and 67% in the FL cohort [&lt;ulink linkID="1426192" linkType="Reference"&gt;1426192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hodgkin's lymphoma&lt;/subtitle&gt;In October 2007, an open-label, North American phase II trial (NCT00543582, CL002, also presumed to be Trial 012) of mocetinostat dihydrobromide in combination with Vidaza  in relapsed or refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma was initiated. A total of 75 patients would be treated with 75 mg/m2 of iv or sc Vidaza  plus an oral dose of mocetinostat dihydrobromide in 28 day cycles. Endpoints would include overall response rate, progression-free survival and duration of response. A pharmacokinetic equivalency study would also be conducted. In December 2007, the trial was expected to complete in August 2008 [&lt;ulink linkID="866530" linkType="Reference"&gt;866530&lt;/ulink&gt;], [&lt;ulink linkID="866278" linkType="Reference"&gt;866278&lt;/ulink&gt;], [&lt;ulink linkID="866200" linkType="Reference"&gt;866200&lt;/ulink&gt;]; in December 2008, the trial was terminated due to the re-acquisition of rights from Celgene [&lt;ulink linkID="866530" linkType="Reference"&gt;866530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2006, a phase II trial (&lt;ulink linkID="25604" linkType="Protocol"&gt;NCT00358982&lt;/ulink&gt;, Trial 010) in patients with relapsed or refractory Hodgkin's lymphoma was initiated in the US and Canada. The open-label, multicenter, 35-patient, 12 to 15 month study would administer 110 mg mocetinostat dihydrobromide3 orally three times weekly to patients who had failed other treatments or whose disease had relapsed, and would determine the drug's viability as a treatment option. Effectiveness was to be measured by the combined total of complete responses, partial responses and patients who experienced stable disease for at least six 4-week cycles. Secondary objectives were to include evaluation of safety, as well as assessment of biomarkers and predictive markers for mocetinostat dihydrobromide [&lt;ulink linkID="685653" linkType="Reference"&gt;685653&lt;/ulink&gt;], [&lt;ulink linkID="734568" linkType="Reference"&gt;734568&lt;/ulink&gt;], [&lt;ulink linkID="783173" linkType="Reference"&gt;783173&lt;/ulink&gt;]. In June 2007, at the 43rd ASCO meeting in Chicago, IL, data were presented from 22 subjects, from which there were 2 deaths and 3 dose reductions. The most common adverse events were nausea and fatigue, seen in nine and eight patients, respectively. From a total of 20 evaluable patients, there were 2 complete responses and 6 partial responses and 3 individuals had disease progression. A total of 60% of patients had a greater than 30% tumor reduction and 45% achieved disease control [&lt;ulink linkID="801165" linkType="Reference"&gt;801165&lt;/ulink&gt;], [&lt;ulink linkID="798213" linkType="Reference"&gt;798213&lt;/ulink&gt;]. In October 2007, the trial was amended to expand enrollment to obtain additional patient experience using an 85 mg oral dose.  At that time, full enrollment was expected to be completed by the end of 2007 [&lt;ulink linkID="835572" linkType="Reference"&gt;835572&lt;/ulink&gt;]. In December 2007, clinical data from this study  were presented at the 49th ASH meeting in Atlanta, GA [&lt;ulink linkID="859832" linkType="Reference"&gt;859832&lt;/ulink&gt;]. In June 2008, clinical data were presented at the 44th annual ASCO meeting in Chicago, IL. Enrollment in the 85 mg cohort was ongoing. In this group, out 15 patients, 0 had complete response, 2 had partial responses, 1 had stable disease [&lt;ulink linkID="912341" linkType="Reference"&gt;912341&lt;/ulink&gt;]. In February 2009, the trial was terminated [&lt;ulink linkID="783173" linkType="Reference"&gt;783173&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;In August 2015, Mirati  agreed to conduct a phase I/II trial of  mocetinostat plus &lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt;'s &lt;ulink linkID="81193" linkType="Drug"&gt;durvalumab&lt;/ulink&gt; for NSCLC [&lt;ulink linkID="1683695" linkType="Reference"&gt;1683695&lt;/ulink&gt;]. In May 2016, an open-label, single group assignement, phase I/II study (&lt;ulink linkID="263752" linkType="Protocol"&gt;NCT02805660&lt;/ulink&gt;; 0103-020) began  in the US to assess the safety and efficacy of  mocetinostat plus durvalumab in patients (n = 119)  with advanced or metastatic solid tumors and NSCLC. At that time, the study was to complete in July 2018 [&lt;ulink linkID="1776217" linkType="Reference"&gt;1776217&lt;/ulink&gt;]. In December 2016, it was reported at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria that the enrollment of patients into the study was opened in June 2016 and was ongoing in the US [&lt;ulink linkID="1882488" linkType="Reference"&gt;1882488&lt;/ulink&gt;]. In March 2017, the company was planning to provide update  in mid 2017 [&lt;ulink linkID="1907374" linkType="Reference"&gt;1907374&lt;/ulink&gt;]; at that time, recruitment of the phase Ib/II trial was  ongoing [&lt;ulink linkID="1908755" linkType="Reference"&gt;1908755&lt;/ulink&gt;].  In August  2017, data from the trial were expected in the second half of 2017 [&lt;ulink linkID="1950915" linkType="Reference"&gt;1950915&lt;/ulink&gt;]. In November 2017, the company was planning to provide phase II  data 		in the first quarter of 2018 [&lt;ulink linkID="1981563" linkType="Reference"&gt;1981563&lt;/ulink&gt;]. In April 2018, phase II data from 23 evaluable NSCLC patients were reported. Data demonstrated that three patients achieved partial responses (two confirmed and one unconfirmed), following a treatment duration of exceeding 44 weeks and the treatment was ongoing. Tumor reductions were observed in 8 out of 23 evaluable patients. Further, the combination was well tolerated with only grade 1 or 2 adverse events. At that time, 31 patients had been enrolled in the trial [&lt;ulink linkID="2027242" linkType="Reference"&gt;2027242&lt;/ulink&gt;].  In November 2018, further clinical data were presented at the 33rd SITC Annual Meeting in Washington DC. Of 29 efficacy evaluable patients with progression on prior checkpoint inhibitor therapy, 5 had confirmed partial response (PR) and 12 had tumor regression. A preliminary Kaplan-Meier estimate of median duration of response was &amp;gt; 5 months. No clear differentiation in clinical efficacy was observed between prior benefit and o prior benefit cohorts. Safety profile was tolerable with manageable adverse events. There was decrease in MDSCs and granulocytic MDSCs in patients at cycle 1 day 15 versus cycle 1 day 1 [&lt;ulink linkID="2093097" linkType="Reference"&gt;2093097&lt;/ulink&gt;], [&lt;ulink linkID="2092788" linkType="Reference"&gt;2092788&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2014, the company planned to initiate a phase II trial in solid tumor patients in mid-2014 and report data by the end of 2014 [&lt;ulink linkID="1557480" linkType="Reference"&gt;1557480&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2006, a phase I/II trial (&lt;ulink linkID="40847" linkType="Protocol"&gt;NCT00372437&lt;/ulink&gt;, Trial 006) of mocetinostat dihydrobromide, in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; (Gemzar) for solid tumors, including pancreatic cancer, began. In the phase I portion, mocetinostat dihydrobromide (50 to 110 mg) plus Gemzar would be administered orally, 3 times weekly for 4 weeks to evaluate the compatibility and safety of the two agents in 60 patients. The study would determine the maximum tolerated dose of the drug to define the phase II dose. Secondary endpoints would include dose-limiting toxicity, objective responses, time to progression and survival. In the expanded phase II portion of the trial, the primary endpoint was the overall response rate in pancreatic cancer patients. At that time, the North American trial was expected to be completed in 2008 [&lt;ulink linkID="783168" linkType="Reference"&gt;783168&lt;/ulink&gt;], [&lt;ulink linkID="734584" linkType="Reference"&gt;734584&lt;/ulink&gt;]. In October 2007, enrollment for this trial was ongoing [&lt;ulink linkID="835572" linkType="Reference"&gt;835572&lt;/ulink&gt;]. In October 2007, interim data were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA.  A total of 21 patients had been enrolled; 13 were available for safety, 13 for efficacy, and 14 for DLT. By that time, 3 doses had been examined: 50, 75 and 90 mg. The ongoing dose was 110 mg and no evidence that the MTD had been reached had been observed. Two DLT had been observed: a grade 4 thrombocytopenia and a grade 3 allergic reaction.  One partial response had been observed. There were eight patients with stable disease, four with progressive disease, eight were not evaluated. The combination of mocetinostat dihydrobromide and gemcitabine showed preliminary evidence of activity, with one partial response observed in one pancreatic cancer patient and significant tumor shrinkage seen in another. AUC and Cmax were not dose-proportionate, with the mean concentration vs time profile and the Cmax lower at 90 mg than at 75 mg [&lt;ulink linkID="844673" linkType="Reference"&gt;844673&lt;/ulink&gt;]. In January 2008, further data were reported at the 2008 Gastrointestinal Cancers Symposium in Orlando, FL. At that time, 14 out of 29 patients from the phase I portion were available for evaluation. There were two confirmed and two unconfirmed partial responses and six patients had stable disease. Enrollment in the phase II portion was ongoing [&lt;ulink linkID="871622" linkType="Reference"&gt;871622&lt;/ulink&gt;]. In June 2008, further data were presented at the 44th annual ASCO meeting in Chicago, IL. The phase II portion of the trial was ongoing, 22 patients had been enrolled at 90 mg/m2. However, 16 had discontinued, mostly due to poor tolerability of the combination [&lt;ulink linkID="913273" linkType="Reference"&gt;913273&lt;/ulink&gt;]; in December 2008, the trial was completed [&lt;ulink linkID="783168" linkType="Reference"&gt;783168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;In August 2007, the company planned a phase I combination trial with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; in patients with solid tumors (&lt;ulink linkID="7951" linkType="Protocol"&gt;NCT00511576&lt;/ulink&gt;, Trial 011). In the non-randomized, open-label, single group assigned safety study, 54 patients were to receive escalating doses of  mocetinostat dihydrobromide in combination with two fixed doses (60 mg/m2 and 75 mg/m2) of  iv docetaxel [&lt;ulink linkID="835616" linkType="Reference"&gt;835616&lt;/ulink&gt;]. The primary endpoints were to determine the MTD, DLTs , safety profile, plasma pharmacokinetics, potential pharmacodynamic effects and overall tumor response  of the drug combination. In October 2007, the company planned to initiate the trial by the end of 2007 [&lt;ulink linkID="835572" linkType="Reference"&gt;835572&lt;/ulink&gt;]. In October 2007, the trial began. In the 50-patient, 12- to 18-month, multicenter, North American study patients would receive mocetinostat dihydrobromide orally three times a week for 3 weeks plus Taxotere administered on day 1 of each three-week cycle. In the first portion of the trial, the maximum tolerated dose of mocetinostat dihydrobromide and the optimal dosing strategy for the second portion of the trial, would be evaluated. In the second portion of the study, tumor response and the combination's pharmacodynamics and pharmacokinetics would be assessed [&lt;ulink linkID="837874" linkType="Reference"&gt;837874&lt;/ulink&gt;], [&lt;ulink linkID="837797" linkType="Reference"&gt;837797&lt;/ulink&gt;]; in December 2008, the trial was terminated due to the re-acquisition of rights from Celgene [&lt;ulink linkID="835616" linkType="Reference"&gt;835616&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2005, a phase I study (&lt;ulink linkID="27759" linkType="Protocol"&gt;NCT00324194&lt;/ulink&gt;, Trial 004) commenced with patients (expected n = 25) with MDS and leukemia, who would be given mocetinostat dihydrobromide orally twice-weekly for a 3-week cycle in doses up to 40 mg/m2 [&lt;ulink linkID="577076" linkType="Reference"&gt;577076&lt;/ulink&gt;], [&lt;ulink linkID="809553" linkType="Reference"&gt;809553&lt;/ulink&gt;]. In December 2006, data were presented at the 48th ASH meeting in Orlando, FL. Of 19 patients receiving continuous twice-weekly doses of either 40, 53, 66 or 83 mg/m2 (n = 6, 7, 3 and 3, respectively), several patients in the 40 mg/m2 cohort had completed 6 treatment cycles, while 1 patient in the highest dose group was still being treated. At that time, accrual at highest dose was ongoing [&lt;ulink linkID="748921" linkType="Reference"&gt;748921&lt;/ulink&gt;], [&lt;ulink linkID="749999" linkType="Reference"&gt;749999&lt;/ulink&gt;], [&lt;ulink linkID="750564" linkType="Reference"&gt;750564&lt;/ulink&gt;].  Recruitment was ongoing in March 2007  [&lt;ulink linkID="809553" linkType="Reference"&gt;809553&lt;/ulink&gt;]. In June 2007, at the 43rd ASCO meeting in Chicago, IL, it was disclosed that the MTD had been reached and the recommended dose for phase II trials was being confirmed [&lt;ulink linkID="795938" linkType="Reference"&gt;795938&lt;/ulink&gt;]. In August 2008, the trial was completed [&lt;ulink linkID="809553" linkType="Reference"&gt;809553&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, the initiation of a dose-escalating phase I trial (&lt;ulink linkID="27754" linkType="Protocol"&gt;NCT00324129&lt;/ulink&gt;, Trial 003) was announced. The study was to involve 35 patients with MDS and leukemia, who would be dosed orally three times per week for a 3-week cycle in doses up to 80 mg/m2 [&lt;ulink linkID="577076" linkType="Reference"&gt;577076&lt;/ulink&gt;], [&lt;ulink linkID="635799" linkType="Reference"&gt;635799&lt;/ulink&gt;], [&lt;ulink linkID="809552" linkType="Reference"&gt;809552&lt;/ulink&gt;]. In December 2005, at the 47th ASH meeting in Atlanta, GA, it was disclosed that 8 AML patients had been enrolled at the 20 and 40 mg/m2 dose levels. At that time, enrollment was ongoing at the 80 mg/m2 dose level [&lt;ulink linkID="640638" linkType="Reference"&gt;640638&lt;/ulink&gt;]. In June 2006, data were presented at the 42nd ASCO meeting in Atlanta, GA, showing that out of 20 patients, 3 achieved complete responses. The MTD was determined at 80 mg/m2 [&lt;ulink linkID="671496" linkType="Reference"&gt;671496&lt;/ulink&gt;], [&lt;ulink linkID="671613" linkType="Reference"&gt;671613&lt;/ulink&gt;], [&lt;ulink linkID="671687" linkType="Reference"&gt;671687&lt;/ulink&gt;], [&lt;ulink linkID="679906" linkType="Reference"&gt;679906&lt;/ulink&gt;]. In August 2006, data presented at the 19th International Medicinal Chemistry Symposium in Istanbul, Turkey, showed that the compound compared favorably to &lt;ulink linkID="8023" linkType="Drug"&gt;romidepsin&lt;/ulink&gt;, MS-275, PXD-101, and SAHA [&lt;ulink linkID="687059" linkType="Reference"&gt;687059&lt;/ulink&gt;]. Recruitment was ongoing in October 2006. In December 2008, the trial was completed [&lt;ulink linkID="809552" linkType="Reference"&gt;809552&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2004, a phase I monotherapy trial (&lt;ulink linkID="24275" linkType="Protocol"&gt;NCT00323934&lt;/ulink&gt;; Trial 002) was initiated in the US and Canada that was to involve 40 patients with advanced solid malignancies refractory to available therapies, including aggressive non-Hodgkin's lymphoma. The dosing schedule was mocetinostat dihydrobromide three times weekly for 2 weeks, both followed by one week's rest [&lt;ulink linkID="809550" linkType="Reference"&gt;809550&lt;/ulink&gt;]. In November 2005, data from Trial 002 were presented at the 17th AACR-NCI-EORTC conference in Philadelphia, PA. Patients (n = 24) with advanced solid tumors were treated with 12.5, 20, 27 or 36 mg/m2 oral mocetinostat dihydrobromide thrice-weekly for 2 of 3 weeks. Of 19 evaluable patients, 12 achieved stable disease and 7 progressed. At that time, enrollment was ongoing to test a 45 mg/m2 dose [&lt;ulink linkID="635799" linkType="Reference"&gt;635799&lt;/ulink&gt;], [&lt;ulink linkID="634832" linkType="Reference"&gt;634832&lt;/ulink&gt;]. In June 2006, at the 42nd ASCO meeting in Atlanta, GA, it was disclosed that 28 patients had been enrolled and had received between 12.5 and 56 mg/m2 of mocetinostat dihydrobromide. Disease stabilization was observed in three renal cell cancer patients and one colorectal cancer patient [&lt;ulink linkID="671162" linkType="Reference"&gt;671162&lt;/ulink&gt;], [&lt;ulink linkID="669989" linkType="Reference"&gt;669989&lt;/ulink&gt;], [&lt;ulink linkID="671613" linkType="Reference"&gt;671613&lt;/ulink&gt;], [&lt;ulink linkID="671687" linkType="Reference"&gt;671687&lt;/ulink&gt;]. Recruitment was ongoing in October 2006 [&lt;ulink linkID="809550" linkType="Reference"&gt;809550&lt;/ulink&gt;].  In November 2006, at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague, Czech Republic, clinical data from 37 enrolled patients and 87 completed treatment cycles were presented. The MTD had been determined as 45 mg/m2, and the agent could be safely administered thrice-weekly on a 2 weeks on/1 week off schedule. At that time, the company amended the trial protocol to examine the effect of the alternate dosing schedule on fatigue [&lt;ulink linkID="741623" linkType="Reference"&gt;741623&lt;/ulink&gt;]; in December 2008, the trial was completed [&lt;ulink linkID="809550" linkType="Reference"&gt;809550&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2004, the first phase I study of mocetinostat dihydrobromide (Trial 001), which was to follow a daily dosing schedule for 2 weeks, had begun. This was to recruit 15 to 30 patients and last for 9 to 12 months [&lt;ulink linkID="546501" linkType="Reference"&gt;546501&lt;/ulink&gt;], [&lt;ulink linkID="547463" linkType="Reference"&gt;547463&lt;/ulink&gt;], [&lt;ulink linkID="547464" linkType="Reference"&gt;547464&lt;/ulink&gt;], [&lt;ulink linkID="635799" linkType="Reference"&gt;635799&lt;/ulink&gt;]. In May 2005, at the 41st ASCO meeting in Orlando, FL, data were presented showing that mocetinostat dihydrobromide was safe and well-tolerated [&lt;ulink linkID="617372" linkType="Reference"&gt;617372&lt;/ulink&gt;]. By November 2005, enrollment had been completed in the phase I dose-escalating trial in solid tumors [&lt;ulink linkID="631726" linkType="Reference"&gt;631726&lt;/ulink&gt;]; by February 2012, the trial had been completed [&lt;ulink linkID="1262196" linkType="Reference"&gt;1262196&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;&lt;subtitle&gt;Mocetinostat dihydrobromide&lt;/subtitle&gt;In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. In NSCLC cell lines, mocetinostat up-regulated expression of programmed cell death receptor-1 (PD-L1), immune co-stimulatory molecules and antigen presentation machinery. In-vivo, mocetinostat increased CD4+ and 8+ cells and the expression of circulating factors and decreased immunosuppressive cell populations [&lt;ulink linkID="1755856" linkType="Reference"&gt;1755856&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 102nd AACR meeting in Orlando, FL. In a Kasumi-1 AML xenograft model, mocetinostat dihydrobromide (150 mg/kg) inhibited HDAC activity, induced acetylation of histone H3, and induced apoptosis and caspase 3/7 [&lt;ulink linkID="1176222" linkType="Reference"&gt;1176222&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Between April 2008 and September 2004, preclinical data on mocetinostat dihydrobromide were presented at the 99th AACR meeting [&lt;ulink linkID="893781" linkType="Reference"&gt;893781&lt;/ulink&gt;], the  98th AACR meeting [&lt;ulink linkID="784318" linkType="Reference"&gt;784318&lt;/ulink&gt;], [&lt;ulink linkID="784319" linkType="Reference"&gt;784319&lt;/ulink&gt;], the 19th International Medicinal Chemistry Symposium [&lt;ulink linkID="687059" linkType="Reference"&gt;687059&lt;/ulink&gt;], the 17th AACR-NCI-EORTC meeting [&lt;ulink linkID="637278" linkType="Reference"&gt;637278&lt;/ulink&gt;], [&lt;ulink linkID="637279" linkType="Reference"&gt;637279&lt;/ulink&gt;], the 96th AACR meeting [&lt;ulink linkID="593617" linkType="Reference"&gt;593617&lt;/ulink&gt;], and the 16th EORTC-NCI-AACR meeting [&lt;ulink linkID="561829" linkType="Reference"&gt;561829&lt;/ulink&gt;], [&lt;ulink linkID="561999" linkType="Reference"&gt;561999&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Mocetinostat dihydrobromide analogs and other HDAC inhibitors&lt;/subtitle&gt;By January 2009, a series of protected lysine-based sulfonamides as HDAC inhibitors had been synthesized and assessed. One of the most active compounds had IC50 values of 0.20, 0.48 and 0.62 microM, against HDAC1, HDAC6 and 293T cells, respectively. In rats, the compound's AUC (po), Cl (iv), Vss, half-life and F values were 0.023 microM/h/(mg/kg), 0.41 l/h/kg, 0.03 l/kg, 1.2 h and 0.5%, respectively. More work is to be done on optimizing the AUC and oral absorption of the compound [&lt;ulink linkID="1047504" linkType="Reference"&gt;1047504&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2008, a series of sulfamides as HDAC inhibitors had been synthesized and tested. One of the most promising compounds had IC50 values of 0.46, 0.06 and 1.8 microM against HDAC-1, HDAC-6 and 293TV cells, respectively. The compound had EC50 values of 0.35 and 0.2 microM against H3Ac and TubAc, respectively [&lt;ulink linkID="1013909" linkType="Reference"&gt;1013909&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, SAR analysis of a series of mocetinostat dihydrobromide analogs were presented at the 232nd ACS meeting in San Francisco, CA. One of the most active compounds exhibited IC50 values against HDAC1 and MTT HCT116 of 0.04 and 0.3 microM, respectively [&lt;ulink linkID="687436" linkType="Reference"&gt;687436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, preclinical data on a series of second generation HDAC inhibitors were presented at the 97th AACR meeting in Washington, DC. A series of thiophenyl substituted benzamides that are CI-994 derivatives were synthesized that had greater HDAC inhibitory activity than their parent compound. One compound displayed IC50 values of 0.05, 0.2, &amp;gt; 20 and &amp;gt; 20 microM against HDAC-1, -2, -6 and -8, respectively. This compound demonstrated antitumor activity in vivo in tumor xenograft models in mice [&lt;ulink linkID="657175" linkType="Reference"&gt;657175&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2005, MethylGene published research that showed HDAC inhibitors could modulate histone methylation to allow for the reactivation of estrogen receptor genes, and thus could have potential in the treatment of breast cancer [&lt;ulink linkID="598443" linkType="Reference"&gt;598443&lt;/ulink&gt;], [&lt;ulink linkID="598468" linkType="Reference"&gt;598468&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, data presented at the 95th AACR in Orlando, FL, indicated that novel isotype-selective HDAC inhibitors which preferentially inhibit HDAC-1 were potent antiproliferative agents [&lt;ulink linkID="533189" linkType="Reference"&gt;533189&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, preclinical data on this series of HDAC inhibitors were presented at the 227th ACS meeting in Anaheim, CA. The aim of this development program was to develop a series of non-hydroxamate HDAC inhibitors. Initially arylsulfonamide-2-aminophenyl cinnamides and 2-aminophenylamides of omega-substituted alkanoic acids were developed. Development work then moved onto the synthesis of N-(2-amino-phenyl)-4-(oxo/dioxo-heteroarylmethyl)-benzamides. Some of the compounds synthesized were able to partially inhibit HDAC with low nanomolar IC50 values. They were also able to induced hyperacetylation of histones, induce expression of p21 and inhibit the proliferation of various human cancer cells, both in vivo and in vitro [&lt;ulink linkID="529461" linkType="Reference"&gt;529461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2003, a series of (2-amino-phenyl)-amides of omega-substituted alkanoic acids had been synthesized. One of the most potent compounds (MGCD-3650, structure shown) inhibited recombinant human HDAC with an IC50 value of 2 microM, exhibited in vitro antiproliferative activity with an IC50 value of 7 microM and caused G2/M cell cycle arrest in HCT116 cell line. The compound showed antitumor activity in several human tumor xenograft models with a tumor growth inhibition of 53% when dosed at 40 mg/kg per day for 3 weeks [&lt;ulink linkID="544654" linkType="Reference"&gt;544654&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2003, MethylGene presented new data at the Gordon Research Conference on Cancer Genetics and Epigenetics in Ventura, CA, showing that inhibitors of HDAC preferentially inhibit cancer cell proliferation, cause cancer cell cycle arrest and induce apoptosis in human cancer cells but not in normal cells. The company designed and synthesized new chemical series possessing improved pharmacological properties, including oral activity [&lt;ulink linkID="475740" linkType="Reference"&gt;475740&lt;/ulink&gt;]. These data were also published in February 2003. One of the promising compounds from the series of sulfonamide anilides exhibited potent selective antiproliferative activity against eight tested human cancer cells with IC50 values ranging from 1 to 10 microM, compared to normal human cell lines. In a mouse model, the compound demonstrated 55% tumor growth suppression when administered daily for 21 days at doses of 40 mg/kg or 50 mg/kg, ip. It was also shown to induce core histone H3 and H4 acetylation as low as 1 microM in a dose-dependent manner [&lt;ulink linkID="486570" linkType="Reference"&gt;486570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2002, MethylGene published research on the design, synthesis and biological results of a series of sulfonamide anilides and trichostatin A analogs as potent HDAC inhibitors, respectively. The inhibitors possessed strong activity on purified recombinant human HDAC enzymes as well as strong antiproliferative activity on a variety of human tumor cells. In subsequent work, MethylGene designed and synthesized additional structurally distinct chemical series possessing improved selectivity, safety, efficacy, and pharmaceutical properties, including oral activity. At this time, MethylGene expected to select a drug candidate within months [&lt;ulink linkID="460317" linkType="Reference"&gt;460317&lt;/ulink&gt;]. Similar data were presented in September 2002 at the 17th International Symposium on Medicinal Chemistry in Barcelona, Spain. The company presented a series of omega-substituted alkanoic acid (2-amino-phenyl)-amides, which inhibited HDAC with IC50 values in the micromolar range [&lt;ulink linkID="463450" linkType="Reference"&gt;463450&lt;/ulink&gt;], [&lt;ulink linkID="467589" linkType="Reference"&gt;467589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2002, simple analogs of trichostatin A (TSA) were prepared and examined as HDAC-1 inhibitors. Four compounds from the series had low nanomolar IC50 (2-5 nM) values that was comparable to TSA (IC50 = 5 nM). All four compounds induced p21 protein expression in T24 human cancer cells, and two of them showed selective growth inhibition in various human cancer cells [&lt;ulink linkID="455855" linkType="Reference"&gt;455855&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, preclinical data were presented on HDAC inhibitors at the 223rd ACS meeting in Orlando, FL. Sulfonamide analogs selectively induced cell-cycle arrest and demonstrated potent antitumor effects in colon cancer xenografts; half-lives ranged from 1 to 3 h [&lt;ulink linkID="447183" linkType="Reference"&gt;447183&lt;/ulink&gt;], [&lt;ulink linkID="446218" linkType="Reference"&gt;446218&lt;/ulink&gt;], [&lt;ulink linkID="446219" linkType="Reference"&gt;446219&lt;/ulink&gt;]. Current leads were not disclosed [&lt;ulink linkID="448784" linkType="Reference"&gt;448784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2001, SAR data for a series of HDAC inhibitors were reported. The most potent compound from the series displayed potent inhibition of HDAC-1 (IC50 = 0.09 microM), potent antiproliferative activity (EC50 = 0.2 microM in an MTT assay) and induced core histone acetylation at doses as low as 1 to 5 microM. In vivo, tumor growth inhibition of 57%, 50% and 41% was observed after ip administration into nude mice bearing sc non-small cell lung carcinoma A549 tumors at doses of 50, 40 and 20 mg/kg respectively; gross toxicity was not observed [&lt;ulink linkID="425947" linkType="Reference"&gt;425947&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in October 2001, preclinical data on a series of HDAC inhibitors were presented at the AACR-NCI-EORTC meeting, Miami Beach, FL. The company showed that sulfonamide anilides regulated the expression of a number of downstream genes involved in cell cycle and apoptosis regulation, such as p21WAF1/Cip1 [&lt;ulink linkID="430485" linkType="Reference"&gt;430485&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By May 2004, MethylGene was seeking to outlicense the program in Europe for development in the territory [&lt;ulink linkID="547465" linkType="Reference"&gt;547465&lt;/ulink&gt;], [&lt;ulink linkID="640583" linkType="Reference"&gt;640583&lt;/ulink&gt;]. In January 2006, MethylGene signed a collaboration agreement with Pharmion for the development of its anticancer HDAC inhibitors, including mocetinostat dihydrobromide, in North America. Under the deal terms, Pharmion would have exclusive rights for Europe, the Middle East, Turkey, Australia, New Zealand, South Africa and certain countries in Southeast Asia. In addition, the deal included MethylGene's pipeline of second-generation HDAC inhibitor compounds for cancer, whereby Pharmion would provide R&amp;amp;D funding for the first year. Pharmion, MethylGene and Taiho would form a Global Development Committee to share data and coordinate the worldwide development program [&lt;ulink linkID="647624" linkType="Reference"&gt;647624&lt;/ulink&gt;]. In August 2006, MethylGene began enrollment in a phase II trial for Hodgkin's lymphoma, triggering milestone payments from Pharmion and Taiho [&lt;ulink linkID="685653" linkType="Reference"&gt;685653&lt;/ulink&gt;]. In September 2008, MethylGene exercised its right to convert to a milestone and royalty payment arrangement with Celgene [&lt;ulink linkID="944609" linkType="Reference"&gt;944609&lt;/ulink&gt;]. However, in October 2008, MethylGene reacquired rights to mocetinostat dihydrobromide from Celgene, terminating its agreement with the company. Under the terms of the termination, Celgene would continue to support the development of the program for a 90-day period [&lt;ulink linkID="956452" linkType="Reference"&gt;956452&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2003, MethylGene entered into a collaboration, license and commercialization agreement with Taiho Pharmaceutical for a small molecule HDAC inhibitor program for oncology. &lt;ulink linkID="18720" linkType="Company"&gt;Taiho&lt;/ulink&gt; was to provide MethylGene with research funding support for eight scientists for at least two years, as well as preclinical and clinical development costs in the US. Taiho was to be responsible for development of the HDAC oncology product in Japan, Korea, Taiwan, and China, and MethylGene was to retain commercialization rights in the rest of the world [&lt;ulink linkID="509670" linkType="Reference"&gt;509670&lt;/ulink&gt;]. This partnership also included for the companies to jointly investigate a next generation HDAC inhibitor molecule [&lt;ulink linkID="640465" linkType="Reference"&gt;640465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2005, MethylGene had developed two biomarker assays for HDAC that measured the pharmacodynamic effect of mocetinostat dihydrobromide in patients [&lt;ulink linkID="617372" linkType="Reference"&gt;617372&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Jonathan Kell, University Hospital of Wales, Heath Park, Cardiff, UK&lt;/para&gt;&lt;para&gt;Submission date: 26 February 2007&lt;br/&gt;Publication date: 21 June 2007&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;&lt;ulink linkType="Company" linkID="23090"&gt;&lt;/ulink&gt;&lt;ulink linkType="Company" linkID="23090"&gt;MethylGene Inc&lt;/ulink&gt;, in collaboration with &lt;ulink linkType="Company" linkID="29253"&gt;Pharmion Corp&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="18720"&gt;Taiho Pharmaceutical Co Ltd&lt;/ulink&gt;, is developing MGCD-0103, an orally available histone deacetylase (HDAC) inhibitor  for the potential treatment of a variety of cancers. Abnormal histone acetylation is frequently observed in human malignancies and HDAC inhibition has been shown to induce differentiation, cell cycle arrest and apoptosis of malignant cells. In preclinical studies, MGCD-0103 inhibited the growth of several cancer cell lines in vitro and of tumors in murine xenografts. In phase I clinical trials, MGCD-0103 at 45 mg/m(2) caused &gt;/= 20% inhibition of HDAC activity in 40% of patients with solid tumors. MGCD-0103 was generally well tolerated with the most common adverse events being nausea and fatigue. In combination with the hypomethylating agent &lt;ulink linkType="Drug" linkID="37370"&gt;azacitidine&lt;/ulink&gt;, MGCD-0103 (60 to 110 mg) reduced the number of haematological malignancies by approximately 30%. MGCD-0103 is currently in phase II trials in patients with lymphoma, leukemia, myelodysplastic syndromes and solid tumors including pancreatic carcinoma. The author concludes that HDAC inhibition with MGCD-0103 presents an important novel mechanism that can be combined with conventional therapeutics to treat currently incurable cancers.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;The silencing of tumor suppressor genes is a critical event in tumorigenesis [&lt;ulink linkType="Reference" linkID="783786"&gt;783786&lt;/ulink&gt;]. Genes can be aberrantly silenced through the modification of histone proteins [&lt;ulink linkType="Reference" linkID="787263"&gt;787263&lt;/ulink&gt;], and the structural modification of histones is regulated mainly by the acetylation/deacetylation of lysine residues [&lt;ulink linkType="Reference" linkID="783795"&gt;783795&lt;/ulink&gt;]. The balance between these two states is crucial in modulating gene expression because it affects the interaction of DNA with transcription factors, regulatory complexes and RNA polymerases [&lt;ulink linkType="Reference" linkID="783795"&gt;783795&lt;/ulink&gt;]. Histone acetylation is associated with an open chromatin structure in which genes can be transcribed. In contrast, deacetylation, which is conducted by a specific group of enzymes called histone deacetylases (HDACs), is associated with a closed structure where genes are 'silenced' [&lt;ulink linkType="Reference" linkID="783794"&gt;783794&lt;/ulink&gt;]. Histone deacetylation is a characteristic feature of tumor cells [&lt;ulink linkType="Reference" linkID="783786"&gt;783786&lt;/ulink&gt;]. HDAC inhibition is associated with cell cycle arrest in G1 and G2, increased differentiation and apoptosis, and inhibition of proliferation, angiogenesis and metastasis [&lt;ulink linkType="Reference" linkID="783786"&gt;783786&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="786927"&gt;786927&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The treatment of hematological tumors with conventional chemotherapy is complicated by severe toxicity, including myelosuppression, infection and mucositis [&lt;ulink linkType="Reference" linkID="787487"&gt;787487&lt;/ulink&gt;]. Furthermore, there is a substantial risk of death during induction therapy, which can reach 10% in cases of acute myeloid leukemia (AML) [&lt;ulink linkType="Reference" linkID="787487"&gt;787487&lt;/ulink&gt;]. Chemotherapy is perceived as having reached maximum tolerated doses and it is unlikely that a novel cytotoxic drug will substantially alter current management strategies. HDAC inhibitors have the potential to be administered as single agents or in combination with either cytotoxic chemotherapy or hypomethylating agents, such as &lt;ulink linkType="Drug" linkID="37370"&gt;azacitidine&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="782296"&gt;782296&lt;/ulink&gt;], and therefore represent an interesting class of novel anticancer agents.&lt;/para&gt;&lt;para&gt;HDAC inhibitors are classified into four main groups: hydroxamic acid derivatives, including the naturally occurring fungal antibiotic trichostatin A [&lt;ulink linkType="Reference" linkID="787525"&gt;787525&lt;/ulink&gt;]; short chain fatty acids, such as valproic acid; cyclic peptides, such as depsipeptides; and phenylene diamines, including benzamide and benzamate derivatives [&lt;ulink linkType="Reference" linkID="783784"&gt;783784&lt;/ulink&gt;]. Several HDAC inhibitors are currently in clinical development, including the hydroxamic acid-type &lt;ulink linkType="Drug" linkID="39159"&gt;belinostat&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="25491"&gt;CuraGen Corp&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="29414"&gt;TopoTarget A/S&lt;/ulink&gt;) in phase II clinical trials for T- and B-cell lymphoma [&lt;ulink linkType="Reference" linkID="647976"&gt;647976&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="685931"&gt;685931&lt;/ulink&gt;], myelodysplastic syndrome (MDS) [&lt;ulink linkType="Reference" linkID="743075"&gt;743075&lt;/ulink&gt;] and multiple myeloma [&lt;ulink linkType="Reference" linkID="750866"&gt;750866&lt;/ulink&gt;]; the depsipeptide &lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="1007694"&gt;Gloucester Pharmaceuticals Inc&lt;/ulink&gt;) in phase II clinical trials for cutaneous T-cell lymphoma (CTCL) [&lt;ulink linkType="Reference" linkID="587713"&gt;587713&lt;/ulink&gt;], multiple myeloma [&lt;ulink linkType="Reference" linkID="641132"&gt;641132&lt;/ulink&gt;] and solid tumors [&lt;ulink linkType="Reference" linkID="689869"&gt;689869&lt;/ulink&gt;]; and &lt;ulink linkType="Drug" linkID="17625"&gt;vorinostat&lt;/ulink&gt; (suberoylanilide hydroxamic acid/SAHA) approved by the FDA for CTCL [&lt;ulink linkType="Reference" linkID="728773"&gt;728773&lt;/ulink&gt;] and in phase III clinical trials for mesothelioma [&lt;ulink linkType="Reference" linkID="676028"&gt;676028&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;MGCD-0103 (&lt;ulink linkType="Company" linkID="23090"&gt;MethylGene Inc&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="29253"&gt;Pharmion Corp&lt;/ulink&gt;), an orally active phenylene diamine derivative, is the focus of this review. This compound is currently undergoing phase I/II clinical trials in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (a nucleoside analog) for the treatment of solid malignancies, including pancreatic carcinoma [&lt;ulink linkType="Reference" linkID="734584"&gt;734584&lt;/ulink&gt;], a disease for which there is currently no effective chemotherapeutic treatment, and in combination with &lt;ulink linkType="Drug" linkID="37370"&gt;azacitidine&lt;/ulink&gt; in patients with AML and MDS [&lt;ulink linkType="Reference" linkID="748898"&gt;748898&lt;/ulink&gt;]. MGCD-0103 is also being evaluated as a monotherapy in phase II clinical trials for B-cell lymphoma [&lt;ulink linkType="Reference" linkID="690867"&gt;690867&lt;/ulink&gt;], non-Hodgkin's lymphoma [&lt;ulink linkType="Reference" linkID="685653"&gt;685653&lt;/ulink&gt;], AML and MDS [&lt;ulink linkType="Reference" linkID="749530"&gt;749530&lt;/ulink&gt;], and chronic lymphocytic leukemia [&lt;ulink linkType="Reference" linkID="783176"&gt;783176&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;MGCD-0103, a 2-aminopyrimidine analog, was synthesized from 4-aminomethyl-benzoic acid methyl ester hydrochloride by converting it to the corresponding 4-guanidinomethyl derivative (77%) using pyrazole-1-carboxamidine hydrochloride in dimethylformamide (DMF) and diisopropylethylamine at room temperature. The guanidine intermediate was refluxed with 3-dimethylamino-1-pyridin-3-yl-propenone in isopropanol to give 4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl]-benzoic acid methyl ester (52%), which was then hydrolyzed with lithium hydroxide in tetrahydrofolate/methanol/water at 40degC, followed by treatment with benzene-1,2-diamine, triethylamine and benzotriazolyloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) in DMF at room temperature to give N-(2-aminophenyl)-4-((4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl)-benzamide (MGCD-0103; 66%) [&lt;ulink linkType="Reference" linkID="776933"&gt;776933&lt;/ulink&gt;]. The synthesis of MGCD-0103 and other analogs was also disclosed in &lt;ulink linkType="Patent" linkID="PA2906819"&gt;WO-2004069823&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;Initial SAR studies to identify HDAC inhibitors were based on SAHA-trichostatin A-like straight chain hydroxamates [&lt;ulink linkType="Reference" linkID="455855"&gt;455855&lt;/ulink&gt;]. These results aided the design of a series of non-hydroxamate HDAC inhibitors, including arylsulfonamide-2-aminophenyl cinnamides and 2-aminophenylamides of omega-substituted alkanoic acids [&lt;ulink linkType="Reference" linkID="463450"&gt;463450&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="467589"&gt;467589&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="486570"&gt;486570&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="544654"&gt;544654&lt;/ulink&gt;]. Optimization of the structural features to improve selectivity, safety and efficacy led to the discovery of MGCD-0103.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;MGCD-0103 selectively inhibited HDAC enzymes 1, 2, 3 and 11 with IC50 values of 0.1, 0.2, 2.0 and 2.0 microM, respectively. However, it has relatively low potency against HDAC 4 to 10 with IC50 values &amp;gt; 20 microM [&lt;ulink linkType="Reference" linkID="776933"&gt;776933&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The antitumor activity of MGCD-0103 was demonstrated in an MTT assay where MGCD-0103 inhibited growth of HCT116 human colon, T24 bladder, A549 lung and MDA-MB-231 breast cancer cells, with IC50 values of 0.2, 1.0, 1.0 and 0.9 microM, respectively [&lt;ulink linkType="Reference" linkID="561999"&gt;561999&lt;/ulink&gt;]. In all cell lines tested, MGCD-0103 demonstrated more potent HDAC inhibitory activity than either MS-275 or SAHA, whose IC50 values ranged from 0.5 to 5 microM. The three compounds only weakly inhibited cell growth in non-cancer breast epithelial HMEC cells (IC50 values ranging from 18 to &amp;gt; 25 microM), indicating a high degree of selectivity for cancer cells. In HCT116 cells, MGCD-0103 (1 and 5 microM) increased apoptosis by approximately 120 and 130% relative to the control, respectively, compared with an increase of approximately 50 and 90% following treatment with 1 and 5 microM of MS-275, respectively. Apoptosis induction was accompanied by dose-dependent inductions in histone acetylation, cell cycle arrest and p21 expression (a cyclin-dependent kinase inhibitor). In T24 cells, immunoblotting with histone-specific antibodies demonstrated that MGCD-0103 (0 to 25 microM) enhanced acetylation and, at 1 and 10 microM, G2M cell cycle arrest was increased from 17 to 53%. In p21-transfected HCT116 cells, MGCD-0103 (0.2 to 5 microM) induced p21 expression (measured in luciferase units) from 400 to 3000 [&lt;ulink linkType="Reference" linkID="561999"&gt;561999&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Additionally, exposure of HCT116 cells to 1 microM of MGCD-0103 or SAHA for 18 h induced a 2.5- and 2.3-fold increase in the expression of the biomarker metallothionein 3 (MT3), respectively [&lt;ulink linkType="Reference" linkID="784319"&gt;784319&lt;/ulink&gt;]. The expression of IL-6 was similarly induced in human leukemia RPMI8226 and Jurkat cells treated for 24 h with MGCD-0103 (1 microM), with IL-6 expression increased by 8.2- and 3.6-fold compared with actin, respectively [&lt;ulink linkType="Reference" linkID="784318"&gt;784318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Treatment of A549, PANC1 ductal pancreatic carcinoma and BxPC3 pancreatic adenocarcinoma cell lines with a combination of MGCD-0103 and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; produced a dose-dependent synergistic inhibition of cell proliferation [&lt;ulink linkType="Reference" linkID="637279"&gt;637279&lt;/ulink&gt;]. In PANC1 cells treated with MGCD-0103 (1.6 microM) or gemcitabine (0.4 microM) for 24 h, cell viability was reduced to approximately 35 and 60%, respectively, while in combination cell viability was reduced to approximately 7%. Similarly, apoptosis and histone acetylation increased synergistically. The effectiveness of the combination was greater when the cells were exposed to gemcitabine for 24 h prior to MGCD-0103 administration for 72 h, as indicated by a complete abolition of cell viability at the doses stated above. The same effect was observed with gemcitabine (0.012 microM) plus MGCD-0103 (0.8 microM) in lung cancer cells. Each drug, when administered alone, reduced cell viability to 22% but in combination cell viability was reduced to 0%. Pretreatment with MGCD-0103 followed by gemcitabine did not produce a synergistic effect [&lt;ulink linkType="Reference" linkID="637279"&gt;637279&lt;/ulink&gt;]. Similarly, in multiple myeloma cell lines NCIH929, RPMI8266 and U266, MGCD-0103 (100 nM) reduced cell viability to 55, 35 and 65%, respectively, and IFNalpha (300 IU/ml) reduced cell viability to 65, 55 and 50%, respectively. In contrast, the reduction in cell viability following combination therapy with both MGCD-0103 and IFNalpha was 35, 20 and 35%, respectively [&lt;ulink linkType="Reference" linkID="636132"&gt;636132&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Ex vivo analysis of white blood cells from human volunteers demonstrated that MGCD-0103 (0 to 600 microM) inhibited HDAC activity from approximately 6000 to 1000 arbitrary fluorescence units (AFU) [&lt;ulink linkType="Reference" linkID="593617"&gt;593617&lt;/ulink&gt;]. In CD1 mice administered MGCD-0103 (30 to 90 mg/kg po), HDAC activity in white blood cells was reduced from approximately 7000 to 5000 AFU after 4 h. Concomitantly, histone acetylation was increased by approximately 2.5- and 3.5-fold after 4 h following administration of 60 and 90 mg/kg of MGCD-0103, respectively [&lt;ulink linkType="Reference" linkID="593617"&gt;593617&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Histone acetylation was approximately 3-fold greater in HCT116-xenografted mice following oral administration of MGCD-0103 (90 or 120 mg/kg) compared with &lt;ulink linkType="Drug" linkID="24087"&gt;MS-275&lt;/ulink&gt; (30 mg/kg). Induction of p21 increased by approximately 1.4- and 1.7-fold after treatment with 90 and 120 mg/kg of MGCD-0103, respectively, compared with MS-275 (30 mg/kg) [&lt;ulink linkType="Reference" linkID="776933"&gt;776933&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;MGCD-0103 also dose-dependently inhibited tumor growth in human xenograft murine models. In A549 xenografts, MGCD-0103 (15 and 30 mg/kg/day ip) inhibited tumor growth by 53 and 82%, respectively. In A431 epidermoid carcinoma xenografts, oral administration of 60 and 90 mg/kg/day of MGCD-0103 inhibited tumor growth by approximately 30 and 60%, respectively. In DU145 prostate carcinoma, oral administration of 70 and 80 mg/kg/day of the drug produced 47 and 81% inhibition, respectively [&lt;ulink linkType="Reference" linkID="561999"&gt;561999&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The synergistic effect of MGCD-0103 with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; was confirmed in nude mice xenografted with A549 and PANC1 tumors. In PANC1 xenografts, intraperitoneal administration of MGCD-0103 (30 mg/kg) plus &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (160 mg/kg) resulted in a 102% tumor growth inhibition and a tumor growth delay of 36 days. This compared favorably with a 66 and 80% inhibition, and 10 and 24 day delay observed after individual administration of MGCD-0103 and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;, respectively. In A549 xenografts, intraperitoneal administration of MGCD-0103 (30 mg/kg) plus &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; (80 mg/kg) resulted in a 76% tumor growth inhibition, while the inhibition was 40 and 45% after individual administration of MGCD-0103 and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;, respectively [&lt;ulink linkType="Reference" linkID="637279"&gt;637279&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No toxicity data for MGCD-0103 have been reported to date.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;In animal models, MGCD-0103 exhibited widely varying oral bioavailability, ranging from 4% in dogs to 42% in rats. The half-life was consistently short among species at 36, 42 and 78 min in mice, rats and dogs, respectively [&lt;ulink linkType="Reference" linkID="776933"&gt;776933&lt;/ulink&gt;]. In CD1 mice administered oral MGCD-0103 (90 mg/kg), average plasma concentrations were 2.3, 0.21 and 0.015 microM after 2, 8 and 24 h, respectively [&lt;ulink linkType="Reference" linkID="593617"&gt;593617&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In patients with advanced leukemia (n = 20), oral administration of escalating doses of MGCD-0103 (20 to 80 mg/m(2)) three-times weekly resulted in a Cmax at 80 mg/m(2) of 169 ng/ml. The AUC was dose-dependent at doses of 20 to 60 mg/m(2), ranging from approximately 300 to 1300 ng.h/ml, with a half-life of 9 h at 60 mg/m(2) [&lt;ulink linkType="Reference" linkID="671496"&gt;671496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;After administration of MGCD-0103 (12.5 to 36 mg/m(2) po) to 24 patients with solid tumors, the Cmax, AUC, half-life, clearance (Cl) and volume of distribution (Vd) at day 1 for the 12.5 mg/m(2) dose were 108.6 ng/ml, 346 ng.h/ml, 6.9 h, 69 l/h and 715 l, respectively, and for the 36 mg/m(2) dose were 80.6 ng/ml, 453 ng.h/ml, 11.3 h, 135 l/h and 2066 l, respectively. At day 12, the respective values were 82.6 ng/ml, 445 ng.h/ml, 7.6 h, 54 l/h and 594 l at 12.5 mg/m(2), and 126 ng/ml, 611 ng.h/ml, 7.1 h, 108 l/h and 1112 l at 36 mg/m(2) [&lt;ulink linkType="Reference" linkID="635799"&gt;635799&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Following oral administration of MGCD-0103 (40 to 83 mg/m(2)) to 19 patients with leukemia or MDS, the half-life ranged from 7 to 11 h and the Tmax from 0.5 to 1 h. The Cmax increased dose-proportionally and was 124 ng/ml at 40 mg/m(2) and 207 ng/ml at 53 mg/m(2) [&lt;ulink linkType="Reference" linkID="748921"&gt;748921&lt;/ulink&gt;]. After three-times weekly doses (of either 20 or 40 mg/m(2)) the half-life of MGCD-0103 ranged from 6.24 to 8.09 h and the AUC values from 260 to 528 ng.h/ml [&lt;ulink linkType="Reference" linkID="640638"&gt;640638&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;MGCD-0103 was evaluated in non-randomized, open-label, dose-escalation, phase I clinical trials (MGCD-0103-001 and -002, henceforth referred to as just the trial number) in patients with aggressive non-Hodgkin's lymphoma or advanced solid malignancies, including colorectal, renal and lung cancers [&lt;ulink linkType="Reference" linkID="635799"&gt;635799&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="669989"&gt;669989&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="688808"&gt;688808&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="688813"&gt;688813&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="741623"&gt;741623&lt;/ulink&gt;]. Preliminary data from 27 patients administered MGCD-0103 (12.5 to 27 mg/m(2) po) either daily (001 trial) or three-times weekly (002 trial) for 2 weeks every 3 weeks suggested induction and prolonged maintenance of histone acetylation [&lt;ulink linkType="Reference" linkID="688813"&gt;688813&lt;/ulink&gt;]. At the time of publication, no additional data were available for the daily-dosing clinical trial (001). In the ongoing three-times weekly trial (002), 34 patients were evaluated at doses escalating to 56 mg/m(2), with results available for 28 patients receiving MGCD-0103 up to 45 mg/m(2) [&lt;ulink linkType="Reference" linkID="669989"&gt;669989&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="741623"&gt;741623&lt;/ulink&gt;]. Disease stabilization was observed in three renal cell cancer patients after four, six and seven cycles, and in one colorectal tumor patient after four cycles. Histone acetylation increased dose-dependently and correlated with HDAC inhibition; 24 h following administration of MGCD-0103 (45 mg/m(2)), approximately 40% of patients achieved &gt;/= 20% inhibition of HDAC activity and 60% of patients had a &gt;/= 50% increase in histone acetylation. In one patient receiving 45 mg/m(2) of MGCD-0103, HDAC activity decreased from 28 to 13 microM and histone acetylation increased from 0.12 to 0.32 AFU after 11 days of treatment [&lt;ulink linkType="Reference" linkID="669989"&gt;669989&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="741623"&gt;741623&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Similar dose-escalation clinical trials were conducted in patients with hematological malignancies, such as high-risk MDS or AML, with oral doses of MGCD-0103 administered either twice weekly (40 to 83 mg/m(2), trial 004; n = 19) [&lt;ulink linkType="Reference" linkID="748921"&gt;748921&lt;/ulink&gt;] or three-times weekly (20 to 80 mg/m(2), trial 003; n = 23) [&lt;ulink linkType="Reference" linkID="640638"&gt;640638&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="671496"&gt;671496&lt;/ulink&gt;] for three weeks (to complete one cycle). Following three-times weekly dosing, three patients (14%) achieved complete remission [&lt;ulink linkType="Reference" linkID="671496"&gt;671496&lt;/ulink&gt;]. Of those patients, one was treated with 60 mg/m(2) of MGCD-0103, while the other two individuals initially received 80 mg/m(2), which was reduced to 60 mg/m(2) in subsequent cycles of treatment. In the responding patients, HDAC inhibition ranged from 23 to 63% and histone acetylation increased by 1.5- to 3.5-fold of baseline. Interestingly, an observed increase in the expression of biomarkers correlated with efficacy. In non-responders, the biomarkers p21, MT3, B-cell translocation gene 1 (BTG1), and growth-arrest and DNA-damage inducible gene (GADD)45a were approximately 1.2-fold that of baseline for all biomarkers, while in responders they were increased by 3.1-, 1.5-, 3.8- and 2.1-fold, respectively [&lt;ulink linkType="Reference" linkID="671496"&gt;671496&lt;/ulink&gt;]. After twice-weekly dosing, HDAC inhibition was dose-independent, and 66% of patients exhibited &amp;gt; 20% HDAC inhibition [&lt;ulink linkType="Reference" linkID="748921"&gt;748921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;Phase I/II clinical trials were recruiting patients to evaluate the feasibility of administering MGCD-0103 in combination with chemotherapy or hypomethylating agents. A non-randomized, open-label clinical trial (006) was to assess the safety and efficacy of administering increasing oral doses of MGCD-0103 plus &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;, three-times weekly for 4 weeks, in patients with refractory solid tumors and locally advanced or metastatic pancreatic carcinoma. The primary endpoint was to establish tolerability and compatibility of the combination in up to 60 patients. At the time of publication, no results were available [&lt;ulink linkType="Reference" linkID="734584"&gt;734584&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="783168"&gt;783168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A similar non-randomized, open-label, uncontrolled clinical trial (005) was to assess the combination of a standard dose of &lt;ulink linkType="Drug" linkID="37370"&gt;azacitidine&lt;/ulink&gt; (75 mg/m(2)/day for 7 days, sc), which is licensed as single agent therapy in advanced MDS, with three-times weekly increasing doses of MGCD-0103 (35 to 135 mg) in three weekly cycles in patients with MDS or AML (expected n = 60) [&lt;ulink linkType="Reference" linkID="783165"&gt;783165&lt;/ulink&gt;]. Initial results from 23 patients (18 AML and 5 high-risk MDS) demonstrated an approximately 30% response rate, including three complete remissions in AML patients at 60, 90 and 110 mg after five, two and three cycles, respectively. In two MDS and one AML patient treated with MGCD-0103 (90 or 110 mg) for two to three cycles, complete remission without neutrophil recovery was achieved after one cycle. Additionally, one AML patient had a partial remission following one cycle of MGCD-0103 at 110 mg [&lt;ulink linkType="Reference" linkID="748898"&gt;748898&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;At the time of publication, several non-randomized, open-label, uncontrolled phase II clinical trials were ongoing with oral MGCD-0103 (110 mg, three-times weekly). The trials were recruiting patients with relapsed and refractory B-cell lymphoma (trial 008, expected n = 82) [&lt;ulink linkType="Reference" linkID="690867"&gt;690867&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="783174"&gt;783174&lt;/ulink&gt;], relapsed and refractory Hodgkin's lymphoma (trial 010, expected n = 35) [&lt;ulink linkType="Reference" linkID="685653"&gt;685653&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="783173"&gt;783173&lt;/ulink&gt;], MDS/AML (trial 007, expected n = 82) [&lt;ulink linkType="Reference" linkID="749530"&gt;749530&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="783171"&gt;783171&lt;/ulink&gt;] and chronic lymphocytic leukemia (trial 009, expected n = 41) [&lt;ulink linkType="Reference" linkID="783176"&gt;783176&lt;/ulink&gt;]. The primary endpoint was to determine the overall response rates. No data were available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;Oral MGCD-0103 was generally well tolerated in all clinical trials to date, with the most common adverse events being fatigue, nausea and vomiting, and less serious side effects of heartburn, dehydration, anorexia and constipation [&lt;ulink linkType="Reference" linkID="669989"&gt;669989&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="671496"&gt;671496&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="741623"&gt;741623&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="748898"&gt;748898&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="748921"&gt;748921&lt;/ulink&gt;]. In the phase I  clinical trial 003, the MTD was reached at 80 mg/m(2), where three out of four patients presented with grade 3 toxicity involving fatigue, nausea, vomiting and diarrhea [&lt;ulink linkType="Reference" linkID="671496"&gt;671496&lt;/ulink&gt;], while in the 004 trial, no MTD was reported at doses up to 83 mg/m(2). In the 004 trial, of the 19 patients with adverse events, one presented with fatigue at 53 mg/m(2), one with weakness at 83 mg/m(2) and one developed prolongation of the QTc interval at 40 mg/m(2) [&lt;ulink linkType="Reference" linkID="748921"&gt;748921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The MTD of MGCD-0103 in the phase I part of the combination trial (005) was 110 mg. In addition to fatigue and dehydration, as was also observed in the monotherapy trials, of 17 patients with adverse events, 5 presented with neutropenic fever and 3 with pneumonia after one cycle of MGCD-0103 [&lt;ulink linkType="Reference" linkID="748898"&gt;748898&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;MGCD-0103 was first claimed generically in &lt;ulink linkType="Patent" linkID="PA203871"&gt;WO-03024448&lt;/ulink&gt;, assigned to MethylGene. The chemical structure is claimed; however, MGCD-0103 is not specifically claimed. A later, related patent family member, &lt;ulink linkType="Patent" linkID="PA2906819"&gt;WO-2004069823&lt;/ulink&gt; specifically claimed MGCD-0103 as a novel HDAC inhibitor. This application was granted as &lt;ulink linkType="Patent" linkID="PA2973995"&gt;US-06897220&lt;/ulink&gt; published in July 2004 which has a US154 extension, bringing its expiry date to 20 September 2022, and was also granted as JP-03795044, which is due to expire on 12 September 2023.&lt;/para&gt;&lt;para&gt;The structure of MGCD-0103 appears to be covered generically in &lt;ulink linkType="Patent" linkID="PA3049598"&gt;WO-2005092899&lt;/ulink&gt;, also assigned to MethylGene, but the specific compound is not disclosed. However, &lt;ulink linkType="Patent" linkID="PA3049598"&gt;&lt;/ulink&gt;WO-2005092899, which continues MethylGene's series of novel HDAC inhibitors, is unrelated to &lt;ulink linkType="Patent" linkID="PA203871"&gt;WO-03024448&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA2906819"&gt;WO-2004069823&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;Further patents associated with MGCD-0103 include &lt;ulink linkType="Patent" linkID="PA3217323"&gt;WO-2006077425&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3217320"&gt;WO-2006077428&lt;/ulink&gt;, both assigned to &lt;ulink linkType="Company" linkID="28026"&gt;Astex Therapeutics Ltd&lt;/ulink&gt;, which relate to drug combinations of pyrazole compounds with anticancer agents or ancillary agents, including HDAC inhibitors such as MGCD-0103. &lt;ulink linkType="Company" linkID="14069"&gt;Altana Pharma AG&lt;/ulink&gt; has a series of applications relating to novel HDAC inhibitors, antiproliferative agents and apoptosis inducers, which claim that the novel compounds may be used in combination with other HDAC inhibitors including, among others, MGCD-0103. This series includes &lt;ulink linkType="Patent" linkID="PA3233276"&gt;WO-2006097474&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3223834"&gt;WO-2006084904&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3223850"&gt;WO-2006084869&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3219594"&gt;WO-2006079644&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3219593"&gt;WO-2006079645&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3215579"&gt;WO-2006075012&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;Although HDAC inhibitors have shown considerable promise, the precise mechanism of action remains unclear and, in particular, it is unclear how MGCD-0103 and other HDAC inhibitors exert preferential effects on tumor cells. It is in understanding this mechanism and its potential for combining HDAC inhibition with other treatment modalities that provides the most excitement for the future.&lt;/para&gt;&lt;para&gt;MGCD-0103 is in the early stages of clinical development and has yet to enter phase III clinical trials; however, phase I/II results are promising. MGCD-0103 dose-dependently inhibits HDAC 1, 2, 3 and 11 at submicromolar concentrations, and dose-dependent hyperacetylation of HDAC 1 was also observed. This narrower spectrum of action, compared with other available inhibitors such as SAHA, which inhibits HDACs 1 to 10 [&lt;ulink linkType="Reference" linkID="289803"&gt;289803&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="787611"&gt;787611&lt;/ulink&gt;], should result in fewer side effects, better tolerability and a greater potential to combine MGCD-0103 with other agents, although results to date are insufficient to draw conclusions. Furthermore, data from a phase I clinical trial in leukemia patients reported the presence of useful biomarkers, with increased expression of p21, MT3, BTG1 and GADD45a observed in responders.&lt;/para&gt;&lt;para&gt;The low incidence of serious adverse events is encouraging; however, large-scale clinical trials have not been conducted. The main side effects reported were fatigue, nausea and anorexia, which are well recognized in patients with malignancy and in those treated with standard chemotherapeutic regimens. However, one patient treated with monotherapy developed prolongation of the QTc interval. This is a potentially serious limiting toxicity and careful observation will be required in the combination trials and in acute leukemia where there is the potential to combine MGCD-0103 with other drugs, including the anthracyline chemotherapeutics, which can cause QT prolongation [&lt;ulink linkType="Reference" linkID="787607"&gt;787607&lt;/ulink&gt;]. Cardiotoxicity was also observed for other HDAC inhibitors, but does not appear to be a major clinical problem when patients are monitored carefully [&lt;ulink linkType="Reference" linkID="787616"&gt;787616&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The non-overlapping toxicity profile (ie, the absence of mucositis and little myelosuppression in combination with chemotherapy) supports the combination of MGCD-0103 with conventional chemotherapy and there will be a great deal of interest in how best to combine these approaches. The synergy reported in preclinical studies in pancreatic carcinoma when MGCD-0103 is administered after conventional cytotoxic therapy raises important questions relating to the sensitization of tumor cells in vivo. It will also be interesting to see how the combination of HDAC inhibitors and hypomethylating agents develops with respect to both efficacy and toxicity, particularly in a subset of MDS patients with monosomy 7, which appears to respond well to &lt;ulink linkType="Drug" linkID="37370"&gt;azacitidine&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="787608"&gt;787608&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase II clinical trials in solid malignancy and hematological disease are ongoing and results may be available in the coming year. As indicated, some of these diseases do not respond well to available therapy; hence, there is an important clinical need for new and effective treatments. Vorinostat was recently approved by the FDA for the treatment of CTCL (an indication that is so far not covered by MGCD-0103) and, therefore, represents the first of the novel HDAC inhibitors to be approved for the treatment of cancer patients. MGCD-0103 is at a similar clinical stage as several other HDAC inhibitors, including &lt;ulink linkType="Drug" linkID="39159"&gt;belinostat&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt;, both in development for MDS and/or solid tumors. These drugs appear to have similar effects but until convincing phase III data are available, it is difficult to say which drug will be most suitable for which disease and which drug is most likely to succeed. Given the early positive data from phase I/II clinical trials of MGCD-0103, the partnership between MethylGene and Pharmion should provide further evidence that the drug has a clinically important future in improving the available treatment options, perhaps particularly in the above-mentioned subset of patients with MDS.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-05-31T00:00:00.000Z</StatusDate><Source id="1776217" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-11-30T00:00:00.000Z</StatusDate><Source id="1873735" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-05-31T00:00:00.000Z</StatusDate><Source id="1776217" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-03-09T00:00:00.000Z</StatusDate><Source id="1908755" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-03-09T00:00:00.000Z</StatusDate><Source id="1908755" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-03-09T00:00:00.000Z</StatusDate><Source id="1908755" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-03-09T00:00:00.000Z</StatusDate><Source id="1908755" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-03-09T00:00:00.000Z</StatusDate><Source id="1908755" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956452" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1771">Transitional cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18720">Taiho Pharmaceutical Co Ltd</Company><Country id="XI">South East Asia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-07T00:00:00.000Z</StatusDate><Source id="749530" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-25T00:00:00.000Z</StatusDate><Source id="783168" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-14T00:00:00.000Z</StatusDate><Source id="634592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-14T00:00:00.000Z</StatusDate><Source id="634592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-06-01T00:00:00.000Z</StatusDate><Source id="910834" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-08-22T00:00:00.000Z</StatusDate><Source id="685653" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-09-15T00:00:00.000Z</StatusDate><Source id="690867" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-02-06T00:00:00.000Z</StatusDate><Source id="783176" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-25T00:00:00.000Z</StatusDate><Source id="734584" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-08-22T00:00:00.000Z</StatusDate><Source id="685653" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29253">Pharmion Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-30T00:00:00.000Z</StatusDate><Source id="647624" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-05-31T00:00:00.000Z</StatusDate><Source id="547463" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-20T00:00:00.000Z</StatusDate><Source id="577076" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-20T00:00:00.000Z</StatusDate><Source id="577076" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-14T00:00:00.000Z</StatusDate><Source id="634592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-11-14T00:00:00.000Z</StatusDate><Source id="634592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-07T00:00:00.000Z</StatusDate><Source id="749530" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-06-01T00:00:00.000Z</StatusDate><Source id="910834" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-09-15T00:00:00.000Z</StatusDate><Source id="690867" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-02-06T00:00:00.000Z</StatusDate><Source id="783176" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-10-25T00:00:00.000Z</StatusDate><Source id="734584" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2380">Bladder cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-07-03T00:00:00.000Z</StatusDate><Source id="1574636" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-06-28T00:00:00.000Z</StatusDate><Source id="1445852" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1085701">Mirati Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1771">Transitional cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-10-20T00:00:00.000Z</StatusDate><Source id="1605498" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18720">Taiho Pharmaceutical Co Ltd</Company><Country id="XI">South East Asia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-20T00:00:00.000Z</StatusDate><Source id="509670" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-20T00:00:00.000Z</StatusDate><Source id="577076" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-12-20T00:00:00.000Z</StatusDate><Source id="577076" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-05-31T00:00:00.000Z</StatusDate><Source id="547463" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29253">Pharmion Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-30T00:00:00.000Z</StatusDate><Source id="647624" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23090">MethylGene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-17T00:00:00.000Z</StatusDate><Source id="425947" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-03-07T00:00:00.000Z</StatusDate><Source id="884216" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1272">Myelodysplastic syndrome</Indication><AwardedIndication>Treatment of myelodysplastic syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-06-12T00:00:00.000Z</MileStoneDate><Source id="1570068" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="161">Hodgkins disease</Indication><AwardedIndication>Treatment of Hodgkin's lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="161">Hodgkins disease</Indication><AwardedIndication>Treatment of Hodgkin's lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-11-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-11-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-02-01T00:00:00.000Z</MileStoneDate><Source id="877220" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-01-31T00:00:00.000Z</MileStoneDate><Source id="875497" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-05T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="161">Hodgkins disease</Indication><AwardedIndication>Treatment of Hodgkin's lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-14T00:00:00.000Z</MileStoneDate><Source id="875497" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="161">Hodgkins disease</Indication><AwardedIndication>Treatment of Hodgkin's lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-08T00:00:00.000Z</MileStoneDate><Source id="824047" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1085701">Mirati Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="161">Hodgkins disease</Indication><AwardedIndication>Treatment of Hodgkin's lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-07-25T00:00:00.000Z</MileStoneDate><Source id="832836" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00326"><Name>Caspase-3</Name><SwissprotNumbers><Swissprot>P42574</Swissprot><Swissprot>P55213</Swissprot><Swissprot>P55866</Swissprot><Swissprot>P70677</Swissprot><Swissprot>Q5IS54</Swissprot><Swissprot>Q60431</Swissprot><Swissprot>Q8MJC3</Swissprot><Swissprot>Q8MJU1</Swissprot><Swissprot>Q8MKI5</Swissprot><Swissprot>Q95ND5</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00330"><Name>Caspase-7</Name><SwissprotNumbers><Swissprot>P55210</Swissprot><Swissprot>P55214</Swissprot><Swissprot>P97864</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00923"><Name>Histone deacetylase-1</Name><SwissprotNumbers><Swissprot>O09106</Swissprot><Swissprot>O42227</Swissprot><Swissprot>P56517</Swissprot><Swissprot>P56518</Swissprot><Swissprot>Q13547</Swissprot><Swissprot>Q91695</Swissprot><Swissprot>Q94517</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00924"><Name>Histone deacetylase-2</Name><SwissprotNumbers><Swissprot>P56519</Swissprot><Swissprot>P70288</Swissprot><Swissprot>Q92769</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00925"><Name>Histone deacetylase-3</Name><SwissprotNumbers><Swissprot>O15379</Swissprot><Swissprot>O88895</Swissprot><Swissprot>P56520</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00926"><Name>Histone deacetylase-4</Name><SwissprotNumbers><Swissprot>O17323</Swissprot><Swissprot>P56524</Swissprot><Swissprot>P83038</Swissprot><Swissprot>Q613L4</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00933"><Name>Histone deacetylase-11</Name><SwissprotNumbers><Swissprot>Q91WA3</Swissprot><Swissprot>Q96DB2</Swissprot><Swissprot>Q9GKU5</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1040632">Otsuka Holdings Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1053033">Stand Up To Cancer</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1085701">Mirati Therapeutics Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15331">Celgene Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29340">Van Andel Institute</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>COc1cc2cccnc2c(c1)NC(=O)[C@H](CCCCNS(=O)(=O)N)NC(=O)OCc3ccccc3</Smiles><Smiles>Cc1ccc(cc1)S(=O)(=O)Nc2ccc(cc2)/C=C/C(=O)Nc3ccccc3N</Smiles><Smiles>c1ccc(c(c1)N)NC(=O)c2ccc(cc2)CNc3nccc(n3)c4cccnc4</Smiles><Smiles>c1ccc(c(c1)N)NC(=O)c2ccc(cc2)CNc3cncc(n3)c4cccnc4</Smiles><Smiles>c1ccc(c(c1)N)NC(=O)c2ccc(cc2)CNc3nccc(n3)c4cccnc4.Br.Br</Smiles><Smiles>COc1ccc(cc1OC)S(=O)(=O)Nc2ccc(cc2)/C=C/C(=O)NO</Smiles><Smiles>c1ccc(cc1)c2ccc(cc2)C(=O)CCCCCCC(=O)Nc3ccccc3N</Smiles><Smiles>c1ccc(cc1)COC(=O)N[C@@H](CCCCNS(=O)(=O)N)c2[nH]c3ccc(cc3n2)c4cccs4</Smiles></StructureSmiles><Deals><Deal id="108610" title="Celgene to develop MethylGene's MGCD-0103"></Deal><Deal id="113227" title="Taiho to develop MethylGene's HDAC inhibitors and sirtuin program for cancer in Japan, Korea, Taiwan and China   "></Deal><Deal id="155691" title="MedImmune and Mirati to conduct phase I/II trial of MEDI-4736 in combination with mocetinostat against NSCLC    "></Deal><Deal id="243444" title="SU2C to award VARI funding to support Phase I/IIb combination study on mocetinostat with guadecitabine and pembrolizumab for NSCLC"></Deal></Deals><PatentFamilies><PatentFamily id="1461517" number="WO-2008012692" title="Assay for efficacy of histone deacetylase inhibitors"></PatentFamily><PatentFamily id="1879698" number="WO-03024448" title="Inhibitors of histone deacetylase"></PatentFamily><PatentFamily id="2183334" number="WO-2009033281" title="Cancer combination therapy with a selective inhibitor of histone deacetylase HDAC1, HDAC2 and/or HDAC3 and a microtubule stabilizer"></PatentFamily><PatentFamily id="654257" number="WO-2004069823" title="Inhibitors of histone deacetylase"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kitakyushu Foundation for the Advancement of Industry Science &amp; Technology" id="1005779"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Methygene Inc" id="1039303"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Otsuka Holdings Co Ltd" id="1040632"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mirati Therapeutics Inc" id="1085701"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celgene Corp" id="15331"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>